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Abstract 
The primary cause of death for cancer patients stems not from the primary tumor, but 
from the spread of the disease to distal sites. Once the cancer has become detectable past 
the point of origin, tumor burden in vital organs is typically too high, limiting the efficacy 
of current treatment options. Development of novel therapies to target disseminated 
cancer cells prior to the onset of extensive metastatic burden could improve patient 
outcomes. Focal therapy, or energy-based ablation, has been successfully used to treat 
solid tumors, but has yet to be effectively applied toward disseminated cells. Microporous 
polymer scaffolds have previously been developed to capture metastatic breast cancer 
cells in vivo, and have been shown to reduce tumor burden in vital organs and improve 
survival. The purpose of this dissertation is to further improve the therapeutic potential of 
these biomaterials by destroying recruited cancer cells. Chapter 1 discusses in further 
detail how these scaffolds recruit metastatic cancer cells and how different types of focal 
therapy have been used to treat solid tumors in the clinic. To demonstrate that focal 
therapy could be used to kill cells within the scaffold, metal disks were integrated into 
polymer scaffolds to serve as a heat source through induction heating for focal 
hyperthermia. It was shown in Chapter 2 that these modified scaffolds could be applied 
successfully to kill infiltrating cells in vivo. The release of cancer-specific antigens 
following ablation of metastatic cells could be utilized to induce an anti-cancer systemic 
immune response. Utilizing melanocytes because of their well-defined tumorigenic 
antigens, collaborative work demonstrated that lysates generated from ablation via 
irreversible electroporation (IRE) resulted in the greatest amount of T cell activation in 
vitro in comparison to focal hyperthermia or cryogenic ablation. Thus, for potential future 
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combinatorial applications with immunotherapy, Chapter 3 investigated methods to 
introduce IRE to polymer scaffolds to treat disseminated cells. To accomplish this, metal 
mesh electrodes were integrated on either side of polymer scaffolds to create a near-
uniform electric field distribution. These modified scaffolds were shown to be capable of 
complete ablation of infiltrating cells upon IRE in vivo in some mice, although further 
refinement is required to eliminate the variability in the response. The amount of antigen 
release from the treatment of recruited cells may be insufficient to induce a robust 
immune response following IRE treatment, and the local delivery of adjuvants may be 
required. Chapter 4 explored how polymer scaffolds could be coupled with inducible 
release of small molecules after electroporation. Scaffolds were modified to facilitate 
conjugation of inducible drug carriers and properties affecting IRE-mediated release were 
investigated to identify optimal conditions. In Chapter 5, polymer scaffolds were 
evaluated for recruitment of melanoma cells in both experimental and spontaneous 
metastasis models such that future studies of the application of combined focal and 
immunotherapy to disseminating tumor cells via biomaterial scaffolds could be 
performed in mouse models in which defined antigens could be used to track the efficacy 
of treatment. Finally, recommendations for future studies were discussed in Chapter 6. 
Altogether, the results of these studies represent an advance in the development of 
treatments that can target metastatic cancer, for which there are currently few effective 
therapeutic options. 
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Chapter 1: Introduction 
1.1 The ongoing battle against breast cancer 
Breast cancer is a leading cause of death for women worldwide. In the U.S., 1 out of 
every 8 women will be diagnosed with breast cancer within her lifetime, with an 
estimated 250,000 new cases each year [1]. Treatment options for many types of cancer, 
including breast cancer, depend greatly on whether the disease is confined to the tissue of 
origin at the time of diagnosis, or if it has already invaded neighboring or distant tissues. 
If the cancer is confined to the breast, the preferred treatment is surgical resection of the 
tumor. To minimize recurrence from cancer cells that may have been left behind after 
surgical resection, many patients also receive local radiation and/or systemic therapies, 
such as chemotherapy. However, if the cancer has metastasized and is detected in distant 
organs or lymph nodes, surgical resection is no longer a feasible option for most patients. 
The most common treatment at this stage is the use of radiation and/or systemic therapies 
[1]. 
 
Metastasis has a drastic effect on long-term survival, not only for breast cancer, but for 
many other types as well (Fig. 1-1). About 90% of cancer mortalities occur when the 
cancer spreads to multiple organs, not from the primary tumor alone [2]. Once the cancer 
has spread, there is often a high tumor burden in vital organs like the brain and lungs, 
making the disease more difficult to treat. Additionally, there are drawbacks to 
conventional systemic therapies that limit their efficacy. Conventional systemic therapies 
for disseminated cancer fall under two main categories: chemotherapy and targeted 
therapy. Chemotherapeutic drugs are designed to kill rapidly dividing cells throughout 
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the body, such as the cancer cells contributing to a growing tumor. In some cases, 
however, the treatment becomes futile as either the growing cancer exhibits resistance to 
 
 
Figure 1-1. Five-year patient survival rates. Chart of five-year survival rates for a variety 
different types of cancer. Bars in black represent patients for whom the cancer has remained 
local, whereas bars in red are patients for whom the cancer has spread. Adapted from [3]. 
 
the drug, and/or the cancer cells spreading throughout the body are in a dormant, non-
proliferating state and therefore not susceptible to chemotherapy. Targeted therapies 
target certain cell receptors specific to, or upregulated on, cancer cells in order to limit 
tumor growth and/or decrease the chance of recurrence. For example, in patients with 
hormone receptor (estrogen and/or progesterone) positive breast cancer, endogenous 
estrogen can promote tumor growth. Drugs such as Tamoxifen are effective at blocking 
estrogen receptors and limiting tumor growth and recurrence. Similar outcomes have 
been achieved for women with human epidermal growth factor receptor 2 (HER2) 
positive tumors using an antibody drug, Trastuzumab, which specifically targets HER2. 
 3 
Unfortunately, breast tumors can be comprised of a heterogeneous population of cancer 
cells, with up to 21 distinct histological subtypes and at least four different molecular 
subtypes [1]. This biological diversity limits the potential of targeted therapies, as the 
treatment may only affect a certain subset of cancer cells throughout the body. 
 
Due to these limitations in conventional therapies, patients diagnosed with advanced 
metastasis suffer from a high tumor burden in their vital organs, and are more likely to 
experience recurrence due to the presence of dormant and/or heterogeneous cancer cells. 
Thus, novel therapeutic strategies that target the metastatic cascade would allow for 
intervention at an earlier stage when the disease burden is still low. 
 
1.2 Mechanisms of metastasis 
An overview of the metastatic cascade is illustrated in Fig. 1-2. Metastasis starts when 
cancer cells from the primary tumor enter circulation through either the lymphatic system 
or the blood vessels by a process called intravasation. Tumor cells entering the lymphatic 
system first accumulate in the draining lymph node of the tumor; detection of such 
accumulation at the draining lymph node is routinely used as a prognostic tool for patient 
survival and for determining the best course of therapy [4]. The majority of tumor cells, 
however, enter the circulatory system through blood vessels, but both forms of entry are 
facilitated by expression of vascular endothelial growth factor (VEGF) [5]. Many of these 
circulating tumor cells (CTCs) do not survive [6], but a small fraction may persist for an 
extended period of time, as long as 22 years in some breast cancer patients [7]. 
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Figure 1-2. Overview of the metastatic cascade. Migrating cancer cells intravasate into adjacent 
blood vessels, upon which they can circulate throughout the body. These cells then reattach to the 
wall of the blood vessel and extravasate to colonize a new location. 
 
Although CTCs are rare, and therefore difficult to isolate, a great deal of effort has been 
made to address this technological challenge. The ability to isolate CTCs from the blood 
of cancer patients could aid in early diagnosis, disease progression, and patient-specific 
cancer cell characterization. To date, many methods have been designed to enrich or sort 
for CTCs, such as flow cytometry [8], microfluidic devices [9], fiber optic array scanning 
[10], high-throughput optical-imaging systems [11], and immunomagnetic-bead 
purification [12]. One of these strategies, immunomagnetic-bead purification, has led to 
an FDA-approved CTC enumeration technology called CellSearch [13]. This technology 
could be used to predict the response to treatment and overall survival in breast cancer 
patients following treatment, as both progression-free and overall survival were 
significantly shorter for patients with high levels of CTCs versus patients with low CTCs 
levels [14]. While the isolation of CTCs has proven to be useful as a diagnostic tool, it 
cannot be used as direct treatment against cancer. 
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The mere presence of CTCs in the blood does not indicate that the cancer has 
successfully metastasized, as the downstream steps in the metastatic pathway are what 
lead to the fatality associated with metastasis. Upon intravasation, CTCs may arrest 
within the blood vessels, and then extravasate and colonize the tissue at a distant site 
from the primary tumor. At the early stages of colonization, the metastatic lesion is only 
composed of a few cells and is virtually undetectable. Currently, modern imaging 
technologies lack the resolution necessary to detect micrometastases (< 2 mm) [15]. 
These micrometastases may remain in a dormant state, undergo apoptosis, or proliferate 
to generate a secondary tumor [16]. Once the secondary tumor has grown large enough to 
detect, the tumor burden in that organ, and potentially others throughout the body, is 
typically high. In these cases, treatment is much more challenging. 
 
The idea that CTCs do not randomly land at sites to colonize is a concept that was 
pioneered by Dr. Stephen Paget in 1889 with his seed-and-soil hypothesis. After studying 
the tumor distribution in patients who died of breast cancer, Paget recognized the 
propensity of certain organs to be “predisposed” for secondary tumors [17]. More recent 
findings have shown that the primary tumor plays a significant role in establishing 
conducive microenvironments, or pre-metastatic niches, prior to colonization. Systemic 
secretion of VEGF from the primary tumor facilitates trafficking of VEGF receptor 1-
positive hematopoietic bone marrow progenitors to establish pre-metastatic niches by 
expressing proteinases, such as matrix metallopeptidase 9 (MMP9), to degrade basement 
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proteins to aid in extravasation and stromal derived factor 1 (SDF-1) to promote 
attachment, survival, and growth of disseminated cells [18]. 
 
The primary tumor also employs immune cells to facilitate recruitment and protection of 
disseminated cancer cells at the pre-metastatic niche. Elevated numbers of macrophage 
antigen 1-positive myeloid cells at the pre-metastatic niche correlate with increased 
metastasis, as these cells secrete tumor migration-stimulation factors, such as tumor 
necrosis factor α, macrophage inflammatory protein 2, and transforming growth factor β 
[19]. Another class of immune cells, Gr1hiCD11b+ myeloid derived suppressor cells 
(MDSCs), are seen at higher levels at the niche prior to tumor cell arrival, and help 
induce expression of MMP9 and SDF-1. In addition, Gr1hiCD11b+ MDSCs inhibit 
interferon (IFN) γ production, a cytokine associated with antitumor cytotoxicity, while 
also increasing expression interleukin (IL)-4, IL-5, IL-9, and IL-10, to stimulate immune 
suppressing T helper 2 (Th2) cells. The combination of decreased IFN γ and Th2 
cytokines protects infiltrating tumor cells from immune surveillance [20].The existence 
of pre-metastatic niches orchestrated by the primary tumor suggests that artificial sites 
could be engineered to mimic these niches. An innovation of this nature could be used as 
a potential therapy to target metastatic disease and ultimately overcome the limitations of 
conventional therapies. 
 
1.3 In vivo models to study metastasis 
For studies focused on engineering biologically complex sites that mimic pre-metastatic, 
selection of the most appropriate animal model is critical. One of the most facile ways to 
 7 
study tumor progression and metastasis is through the transplantation of tumor cells into 
the animal. Immunocompetent animal models have an intact immune system consisting 
of both a full innate and adaptive immune system. The innate immune system, which 
includes macrophages, neutrophils, and natural killer cells, is a first line of defense for 
detecting and eliminating commonly encountered pathogens, such as bacteria, viruses, 
fungi, and parasites. If an unrecognized pathogen overwhelms the innate immune system, 
the adaptive immune system is activated, which uses B and T cells to specifically 
recognize and destroy the foreign pathogen [21]. Conversely, immunocompromised 
models have genetic mutations to knock out T cell, or both T and B cell function, 
inhibiting their adaptive immune system. Immunocompetent models are used for 
syngeneic models, where the tumor and host tissue are of the same species. This is 
particularly advantageous in studying metastasis, since the interaction between the tumor 
and the host incorporates the entire immune system. Immunocompromised models, 
however, are useful in studying metastasis of human cancer through xenograft models, as 
the lack of adaptive immunity means that foreign cancer cells will not be rejected [22]. 
 
Furthermore, injected tumor cell models that result in either spontaneous or experimental 
metastasis have been employed to study metastasis to engineered materials. Spontaneous 
metastasis involves establishing a primary tumor at an orthotopic (in organ or tissue of 
origin) or ectopic (outside of origin) site and allowing it grow and spread. It is preferable 
to model metastasis from an orthotopic site, such as breast cancer inoculated into the 
mammary gland, because it more closely mimics the spread of cancer in a clinical setting; 
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however, only a few cancer lines are capable of metastasizing through this route. 
Common cancer lines for spontaneous metastasis upon orthotopic injection include 
human MDA-MB-231 and murine 4T1 breast cancer lines. The human MDA-MB-231 
cell line is a hormone receptor negative (estrogen and progesterone) and HER2 negative 
cancer line isolated from metastatic cells found in excess fluid in the lungs of a patient 
with breast cancer [23]. The 4T1 line is isolated from a spontaneously arising murine 
mammary tumor [24]. Both the 4T1 and MDA-MB-231 lines metastasize from an 
orthotopic site to vital organs, such as the liver and lung, as observed clinically [24, 25]. 
 
Experimental metastasis circumvents the primary tumor growth process and intravasation 
and instead introduces cancer cells directly into circulation system through either an 
intraperitoneal, intravenous, or intracardiac injection. Since there is no primary tumor in 
this method, experimental metastasis models may not reflect the systemic inflammatory 
effects caused by the primary tumor, including those at the pre-metastatic niche. 
Experimental metastasis is still widely utilized because it requires a shorter time frame to 
detect metastasis. Additionally, the disease can be targeted to a specific site of interest 
with a larger variety of cancer lines [25]. A common cell line for experimental metastasis 
used in research is the murine B16-F10 cell line, isolated from spontaneous melanoma 
found on the ear [26]. This cell line reproducibly colonizes the lung following a tail vein 
injection. While this cell line has can also spontaneously metastasize to the lungs from an 
orthotopic injection, it does so much less efficiently than a more aggressive variant, B16-
BL6 [27]. A better understanding of how artificial metastatic sites attract cancer cells can 
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be attained using both spontaneous and experimental models. Nevertheless, the 
shortcomings of each method lead to difficulties in understanding the complete picture of 
metastasis in a clinical setting. 
 
1.4 In vivo recruitment of cancer cells using biomaterials 
The first efforts to generate an engineered pre-metastatic niche using animal models 
focused on mimicking the skeletal microenvironment, due to the high propensity for 
many types of cancer, including breast cancer, to metastasize to the bone. To study 
human breast cancer metastasis to bone, researchers extracted bone cores from human 
femurs and implanted them subcutaneously in the flanks of immunocompromised mice. 
Histological analysis of harvested bone implants demonstrated their ability to recruit 
HER2 positive human breast cancer cells (SUM1315) [28]. Reproducibility, however, 
was an issue due to the inherent variability of bone implants from different patients. 
 
Efforts then shifted to creating artificial sites that could mimic the skeletal 
microenvironment, which was first accomplished by seeding human bone marrow cells 
into porous scaffolds made from lyophilized silk fibroin coupled with bone 
morphogenetic protein-2. The artificial bone-mimicking materials were able to recruit 
human breast cancer cells in a similar manner as the human bone implants [29]. These 
materials have also been used to recruit MDA-MB-231 human breast cancer cells from 
an orthotopic inoculation in immunocompromised mouse models, as well as murine B16-
F10 melanoma cells inoculated directly into the bloodstream using immune competent 
mice [30]. Other bone-mimicking scaffolds made from synthetic polymers have been 
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used to recruit disseminated cells. Polyacrylamide scaffolds seeded with human bone 
marrow cells have been shown to recruit the PC-3 human prostate cancer cells following 
an orthotopic inoculation [31]. Electrospun polycaprolactone (PCL) scaffolds loaded with 
bone morphogenetic protein-7 and seeded with human osteoblasts have been shown to 
capture human breast (MDA-MB-231) [32] and prostate (PC-3) cancer cells [33] after 
intracardiac injection. However, the need to mimic an organ-specific microenvironment, 
limits the potential of the artificial metastatic site because it attracts the population of 
cancer cells seeking that certain site. A system that uses a broader approach to recruiting 
metastatic cells could have a greater impact as a therapeutic tool. 
 
In one example of a system that is not organ-specific, a network of human blood vessels 
was generated from a basement membrane-like matrix seeded with both human 
endothelial and mesenchymal cells. In immunocompromised mice, human breast cancer 
cells (MDA-MB-231) metastasized from the primary tumor and extravasated through this 
human blood vessel network [34]. Another system used polymer scaffolds to replicate the 
microenvironment found in the peritoneal cavity in patients with ovarian cancer. Unlike 
most other types of cancer that metastasize through the vascular system, ovarian cancer 
can spread to other organs throughout the peritoneum. As the primary tumor grows, 
cancer cells disseminate as single cells or multicellular spheroids from the tumor and 
metastasize in the ascites fluid throughout the peritoneal cavity [35]. To mimic this 
microenvironment, polymer scaffolds made out of PCL or polystyrene have been 
modified with exosomes isolated from human ascites fluid from ovarian cancer patients. 
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These exosomes have been shown to act as signaling vesicles, thus mediating homing of 
disseminated cancer cells. 
 
The exosome-loaded scaffolds altered the metastatic profile of SKOV3 human ovarian 
cancer cells in the intraperitoneal cavity by attracting these cancer cells to the engineered 
scaffold implanted in mice. This method lowered the tumor burden of nearby key organs, 
such as the pancreas, and led to a 100-day improvement in survival. The therapeutic 
benefit of the scaffold was further enhanced by explanting it to remove recruited ovarian 
cancer cells, which resulted in 75% of the mice surviving past the endpoint of the study. 
This study showed that engineered scaffolds could be used as a therapeutic tool against 
cancer by capturing disseminated cells, resulting in lower tumor burden in vital organs 
and increasing overall survival [36]. 
 
Another approach has been to use acute inflammatory responses to recruit metastatic 
cancer cells. Inflammatory cells play important roles in tumor progression, including 
facilitating metastasis [37]. In one study, a solution of microparticles was injected into 
the dorsal subcutaneous space of immunocompetent mice. Murine melanoma (B16-F10) 
cells were then inoculated into the intraperitoneal cavity, and these cells were found to 
have quickly metastasized to the microparticle injection site. Regardless of the 
composition of microparticles used, which included polylactic acid, aluminum hydroxide, 
and glass, a positive correlation was observed between the number of melanoma cells 
recruited and the number of inflammatory cells at the injection area. This broader 
approach was also found to be efficacious in recruiting human breast (MDA-MB-231) 
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and prostate (PC-3) cancer, as well as murine lung cancer (Lewis lung carcinoma). 
Interestingly, there was also a positive correlation between the number of recruited 
melanoma cells and survival. This approach, however, only worked well under acute 
inflammatory conditions. The amount of recruited melanoma cells decreased sharply with 
the length of time the microparticles were implanted, severely limiting the system’s 
therapeutic potential for any long-term use [38]. More importantly, this study only 
utilized an experimental metastasis model. Thus, the study does not reflect the clinical 
progression of metastasis, nor does it take into account the systemic inflammatory 
changes resulting from an established primary tumor.  
 
Another approach by Azarin et al. utilized microporous polymer scaffolds to act as a pre-
metastatic niche by emulating the immune cell populations found in metastatic organs 
[39]. Upon implantation in mice with orthotopic breast tumors, the immune cell 
populations found in the scaffolds were similar to those in the lung, a common site of 
breast cancer metastasis. Consequently, human MDA-MB-231BR (a highly metastatic 
variant of the MDA-MB-231 cell line [40]) and mouse 4T1 breast cancer cells 
metastasized to the scaffolds when they were implanted in the intraperitoneal cavity or 
the subcutaneous space, even when the scaffolds were not functionalized with cells, 
extracellular matrix proteins, or soluble factors prior to implantation. Recruitment was 
associated with an increase in the prevalence of Gr1hiCD11b+ MDSCs in the scaffolds. 
As such, increasing the number of Gr1hiCD11b+ cells, either by localized expression of 
CCL22 or by seeding these cells directly into the scaffold prior to implantation, resulted 
in increased recruitment of breast cancer cells to the scaffold [39]. The notion that 
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MDSCs are involved in recruitment is not surprising, given the various roles they play in 
promoting metastasis, as described above. Furthermore, depletion of this immune 
population through systemic delivery of an anti-Gr1 antibody increased the survival of 
mice with breast cancer [41]. Further studies evaluating the mechanism of MDSC-based 
recruitment to the scaffold identified that MDSCs secrete soluble factors that induce 
tumor cell migration, including haptoglobin, which interacts with the CCR2 receptor 
[42], a receptor that is upregulated in breast cancer cells and tissues [43]. Incorporation of 
recombinant haptoglobin into polymer scaffolds caused a significant increase in MDA-
MB-231BR recruitment, demonstrating a potential mechanism through which 
Gr1hiCD11b+ cells may mediate metastasis to the scaffold [42]. This scaffold technology 
could have broad therapeutic applicability since the recruitment of tumor cells is 
mediated by the local metastatic immune environment, which is not organ-specific, and 
immune cells have been shown to regulate metastasis in multiple types of cancer [19, 44-
50]. 
 
Further demonstrating the robustness of the approach, the presence of scaffolds 
composed of either PCL or poly(lactide-co-glycolide) (PLG) also decreased the tumor 
burden in vital organs such as the lung, liver, and brain, in both human and murine breast 
cancer models [39, 41]. The decrease in metastatic tumor burden led to an increase in 
survival in a more clinically relevant primary tumor resection model, which was designed 
to evaluate the long-term survival from disseminated cancer cells. Approximately 40% of 
mice with scaffolds survived until the end point of the study (200 days), whereas none of 
the mice without scaffolds survived past 40 days [41]. In addition to the therapeutic 
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potential of the system, cancer cells can be detected in the scaffold prior to detection in 
typical metastatic sites, such as the lung, liver, and brain [39, 41]. 
 
While the polymeric scaffolds alone did show some therapeutic benefit, a growing body 
of research has demonstrated that disseminated tumor cells are not bound to remain in 
one location. Both reseeding of the primary tumor site [51] and direct spreading from one 
metastatic site to another [52] have been observed. This observation suggests that the 
recruitment of cancer cells to an artificial site might only delay the eventual reseeding of 
vital organs. Thus, developing strategies to kill these recruited cells could potentially 
increase the therapeutic potential of polymeric tumor-capturing scaffolds. In addition, 
since these scaffolds capture metastatic cells early in disease progression, they offer the 
potential to treat metastasis before the disease burden is too high. The goal of this thesis 
is to modify polymeric tumor-capturing scaffolds so they can be combined with focal 
ablation therapies in order to develop novel treatments for metastatic disease that 
will be applicable across multiple types of cancer. 
 
1.5 Focal therapies and immunotherapies 
As mentioned previously, a common strategy for killing tumor cells is the use of 
chemotherapeutic drugs. These drugs have been utilized in polymeric scaffolds as a 
method of drug delivery, a concept that has been studied in great detail [53]. The long 
release timescales of chemotherapeutic drugs required to kill recruited cancer cells, 
however, would not be practical in a polymeric scaffold designed to capture disseminated 
cancer cells. Additionally, the development of chemoresistance would remain a challenge 
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[54]. Focal therapies, such as thermal ablation [55], cryoablation [56], and irreversible 
electroporation (IRE) [57], have been successfully used to treat cancer by killing cells 
locally at the primary tumor site. These focal therapies have proved to be particularly 
effective for non-resectable tumors. By treating locally, focal therapy avoids some of the 
drawbacks of chemotherapy, which as a systemic approach, leads to toxic side effects in 
healthy tissue. Focal therapy has thus far only been successfully used against solid 
tumors, but the ability to capture disseminated cancer cells could allow for the use of 
focal therapy to target metastasis as well. 
 
Thermal ablation, also known as focal hyperthermia, has been used to treat cancerous 
tissues throughout human history, with written records going as far back as the Egyptian 
times in 3000 BC [58]. More recently, thermal ablation has been used clinically for bone, 
liver, breast, kidney, lung, and prostate cancer [59-61]. Focal hyperthermia uses 
prolonged exposure to elevated temperatures, 42 - 46 °C, to denature intracellular 
proteins, resulting in an exponential decrease in cell survival with thermal exposure [62]. 
However, this temperature range requires treatment for many hours, which can lead to the 
acquisition of thermotolerance [63]. Recently, localized heating to over 50 °C for minutes 
or even seconds has been shown to effectively kill cells while mitigating the risk of 
thermotolerance [64, 65]. Traditional focal hyperthermia techniques have used invasive 
thermal probes to target solid tumors, but less invasive methods have recently been 
developed through electromagnetic induction of thermal seeds using an oscillating 
magnetic field within a radiofrequency coil [66, 67]. 
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Cryoablation works instead by using freezing temperatures to kill cells. Iced saline 
solutions were first used as an anesthetic for patients with advanced breast and uterine 
cancer, but detrimental effects of cold temperatures on cancer cell viability were first 
noted in the 1840s. With advancements in technology, modern cryoablation utilizes 
hollow probes and adiabatic cooling to reach temperatures as low as –190 ºC [68]. These 
cryogenic temperatures cause an iceball to form, subjecting the tumorous tissue to 
lethally cold temperatures of –20 ºC to –40 ºC. At these temperatures, freezing the 
extracellular space causes an increase in extracellular solute concentration. This increase 
then leads to cellular dehydration and eventual ice formation within the cell, which can 
cause damage to the organelles and cell membrane. Further cellular damage occurs upon 
thaw. The intracellular space becomes hypertonic, causing a strong influx of water into 
the cell, and leading it to burst [55]. This powerful tool has been used clinically for 
kidney, liver, prostate, breast, and musculoskeletal cancer [69]. 
 
IRE is an emerging soft tissue ablation technology that was first commercialized in 2009. 
This technique uses the principles of electroporation, which is the use of electric fields 
delivered in periodic pulses to induce pores in the cell membrane and significantly 
increase transmembrane permeability [70]. At modest field strengths and pulse durations, 
the opening of the cell membrane is reversible, having little to no effect on cellular 
viability [71]. Reversible electroporation is now a common technique that has been 
applied to deliver nonpermeable molecules into cells, such as DNA for gene delivery 
[72]. However, at strong enough electric field strengths, the pore formation is irreversible 
and leads to a loss in cellular viability [57]. Although a relatively new treatment method, 
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IRE has shown effectiveness for patients with liver, kidney, pancreas, and prostate cancer 
[73]. 
 
Although focal therapy has been shown to be an effective alternative to surgical 
resection, intervention may fail to treat the entire tumor and/or the cancer cells may have 
already metastasized elsewhere, which may lead to recurrence. To improve the efficacy 
of focal therapy, combinatorial strategies involving systemic immunotherapy have been 
investigated. Due to the mutations associated with cancer, immunotherapy employs the 
host’s immune system to target tumor-specific antigens to recognize and attack cancer 
cells throughout the body [74]. Achieving anti-cancer immunity remains a grand 
challenge, but several novel strategies have garnered clinical relevance over the past 30 
years. To stimulate natural killer cell induction, early strategies administered high doses 
of cytokine IL-2 [75], which received FDA approval for patients with metastatic kidney 
and melanoma in 1992 and 1998, respectively [76]. Recent approaches have utilized 
immune checkpoint blockade inhibitors, such as antibody drugs against CTLA-4 and PD-
1, to target cancer by blocking inhibitory pathways naturally found in the immune 
system. Three immune checkpoint blockade inhibitors have been approved by the FDA 
within the past decade for a variety of advanced cancer types: melanoma, lung, kidney, 
bladder, lymphoma, and gastric cancer [77]. Most recently, the FDA approved the use of 
an adoptive cell therapy that utilizes chimeric antigen receptor (CAR) T cells to treat 
leukemia. CAR T cell therapy involves genetically engineering a patient's endogenous T 
cells to eliminate malignant cells by inducing expression of a T cell receptor specific for 
a desired surface antigen [78]. Despite the immense progress made in immunotherapy 
 18 
strategies towards treating disseminated cancer, the drawbacks from current 
immunotherapy options, mainly immune checkpoint blockade inhibitors and CAR T cell 
therapy, limit their efficacy. Immune checkpoint inhibitors exhibit low response rates, 
with 1 in 2 melanoma patients resisting treatment and enduring disease progression [79]. 
The long and expensive wait times required to harvest and genetically engineer a 
patient’s T cells for CAR T cell therapy also restricts its widespread application [80]. In 
addition, neither option has been successful in treating solid tumors, which have strong 
immunotolerance capabilities. 
 
Combinatorial strategies involving focal and immunotherapy options have shown 
promise at treating solid tumors while also killing disseminated cells. In one study, 
immunocompetent mice with melanoma tumors were treated with either thermal or 
cryoablation with or without immune checkpoint inhibitors. Following treatment, the 
mice were given a secondary tumor challenge. Regardless of focal therapy, mice that 
received immune checkpoint inhibitors exhibited enhanced overall survival compared 
those that received focal therapy alone. Interestingly, some mice that received only focal 
therapy developed tumor immunity without the need for immune checkpoint inhibitors, 
and had greater overall survival under cryoablation versus thermal ablation [81]. Thus, 
ablation of cancer cells from a primary tumor releases tumor-specific antigens that can 
serve as a vaccine against cancer, and the effectiveness of the vaccine can be dependent 
on the focal therapy conditions. The use of tumor lysates as a vaccine has also been 
demonstrated with microporous polymer scaffolds. Scaffolds loaded with tumor lysate 
from ex vivo cryoablation of murine melanoma tumors were implanted subcutaneously in 
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the left flank. Mice with growing melanoma tumors that received these loaded scaffolds 
experienced a decrease in tumor growth and an improvement in overall survival [82]. As 
a consequence, lysing tumor cells within the patient could lead to anti-tumor immunity, 
which may be possible even if the cancer is disseminated with no primary tumor present. 
While many advances have been made in the clinical use of focal therapies, they have yet 
to be used to target disseminated cancer cells. The ability to target disseminated cancer 
cells could lead to earlier intervention and possible immunity for patients with metastatic 
disease. 
 
1.6 Scope and organization of thesis 
The scope of this thesis is to improve the therapeutic potential of tumor cell-recruiting 
polymer scaffolds by integrating focal therapy strategies to kill recruited tumor cells in 
vivo in a manner that can promote an immune response against remaining tumor cells 
throughout the body. Chapters 2 and 3 will focus on modifying the PCL scaffold to kill 
cells through focal hyperthermia and IRE, respectively. In Chapter 4, drug carriers will be 
incorporated into PCL scaffolds for controlled release upon focal therapy in order to 
modulate the local environment for enhanced anti-tumor immune reaction. In Chapter 5, 
PCL scaffolds will be analyzed for the ability to recruit melanoma cells to study potential 
immunotherapy strategies, as unlike breast cancer cells, melanoma cells have defined 
antigens that can be tracked for proof-of-principle immunotherapy studies. Future 
directions that warrant exploration will be discussed in Chapter 6. 
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Chapter 2: Development of polymer-metal composite scaffolds for focal 
hyperthermia 
 
Adapted with permission from “Pelaez, F., Manuchehrabadi, N., Roy, P., Natesan, H., 
Wang, Y., Racila, E., Fong, H., Zeng, K., Silbaugh, A.M., Bischof, J.C., and Azarin, 
S.M. Biomaterial Scaffolds for non-invasive focal hyperthermia as a potential tool to 
ablate metastatic cancer cells. Biomaterials, 2018, 166, 27-37.” Copyright 2018 Elsevier 
Ltd. 
 
2.1 Introduction 
As discussed in section 1.5, applying a focal ablation therapy such as hyperthermia with 
biomaterial scaffolds that recruit metastatic cells could provide novel options for treating 
disseminating cancer. Biomaterial scaffolds have been modified for focal hyperthermia 
for various applications [83-86]. Focal hyperthermia initiated by near-infrared light has 
been shown in polydopamine-coated 3D-printed bioceramic scaffolds [83] and gold 
nanoparticle-containing gelatin biomaterials [84]. PCL scaffolds have also shown 
potential for hyperthermia with embedded magnetic nanoparticles for induced heating in 
oscillating magnetic fields [85, 86]. However, none of these biomaterials have been 
shown to recruit metastatic cancer cells. 
 
Rapid heating through an oscillating magnetic field can be achieved by inducing large 
eddy currents in a conducting material [87]. Thus, we hypothesized that incorporation of 
metal disks into microporous polymeric scaffolds that have previously been shown to 
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capture metastasizing cells in vivo would enable non-invasive application of focal 
hyperthermia to infiltrating cells. The work described in this chapter sought to 
characterize the heat generation and tissue ablation of these polymer-metal composite 
scaffolds. 
 
2.2 Materials and methods 
Metal disk fabrication and coating 
Metal disks were made using four different-sized custom punches on a 0.1 mm thick 
Puratronic aluminum foil (Alfa Aesar) or 0.1 mm thick Puratronic copper foil (Alfa 
Aesar) to generate disks with varying diameter. Following fabrication, disk size was 
measured by image analysis using ImageJ. To coat metal disks with a polymer film, 1.70 
mm Al disks were dipped once into a 10% (w/w) solution of PCL (DURECT; inherent 
viscosity = 0.65-0.85 dL·g-1) in dichloromethane (Sigma). Coated disks were dried 
overnight. To characterize the polymer coating thickness, partial removal of the coating 
was performed using a razor blade, and step height across the interface of the coated and 
uncoated regions was measured using a Tencor P10 profilometer. 
 
Composite scaffold fabrication 
To fabricate composite scaffolds, PCL microspheres were first prepared as previously 
described [41]. Briefly, a 6% (w/w) solution of PCL (DURECT; inherent viscosity = 
0.65-0.85 dL·g-1) in dichloromethane was emulsified in a 10% (w/w) poly(vinyl alcohol) 
solution and homogenized at 10,000 rpm for 1 minute. Microspheres were lyophilized for 
48 hours. PCL microspheres and sieved sodium chloride particles (250-425 µm) were 
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mixed in a 1:30 (w/w) ratio. PCL-coated metal disks were layered between two PCL 
microsphere/sodium chloride mixtures in a 5 mm steel die (Specac), and the contents 
were pressed to 3,300 lbs. for 45 seconds. The pressed disks were heated at 60 ºC for 5 
minutes on each side followed by foaming at 800 psig for ~24 hours, after which the gas 
was released at 17.5 CFH. Salt particles were removed by immersing disks in water for 
90 minutes on a rocking platform. Composite scaffolds were sterilized by soaking in 70% 
ethanol, followed by rinsing with sterile water and drying on a sterile gauze pad. 
Scaffolds were then stored at -80 ºC until further use. 
 
Scaffold implantation 
Animal studies were performed in accordance with institutional guidelines and protocols 
approved by the University of Minnesota Institutional Animal Care and Use Committee 
(IACUC). BALB/c mice were purchased from The Jackson Laboratory, and mice were 8-
31 weeks of age at the time of surgery. Two scaffolds were implanted into the 
subcutaneous space of the upper dorsal region per mouse. Experiments on tissue-laden 
scaffolds were performed 3-10 weeks following implantation. 
 
Tissue sectioning and histological analysis 
Tissue-laden scaffolds for histology were removed whole from the subcutaneous space at 
3-4 weeks post-implantation. The tissues were fixed in 10% buffered formalin, embedded 
in paraffin, and sectioned at 4 µm using an HM 315 microtome (Microm). Slides were 
stained with hematoxylin and eosin (H&E) for histological analysis. Slides were imaged 
using an EVOS FL Auto Microscope (Thermo Fisher Scientific). 
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Inductive heating studies 
A 1 kW inductive heating system with a 2.75 turn, water-cooled, 1.75 cm inner diameter, 
copper coil (Ameritherm Inc.) was used to generate an alternating magnetic field for 
inductive heating experiments. The coil current was adjusted to achieve different 
magnetic field strengths as previously described [67]. Briefly, COMSOL version 5.2a 
(COMSOL, Inc.) was used to calculate the volume-averaged value of the field strength 
across the sample. The resonant frequency used for all studies was 360 kHz. For heating 
studies with bare metal disks, the disks were placed at the bottom of a 2 mL 
microcentrifuge tube with 1 mL of distilled water. A type T thermocouple (OMEGA 
Engineering), model 5TC-TT-T-40-36, was placed on the metal disk to measure the 
surface temperature. This assembly was placed in the center of the copper coil and an 
oscillating magnetic field was applied for 15 minutes. For in vitro heating studies of 4T1 
breast cancer cells (ATCC CRL-2539), one million 4T1 cells were encapsulated in 30 µL 
of 5 mg·mL-1 Matrigel (Corning) surrounding a 1.70 mm Al disk. Samples to be treated 
were placed in the induction coil set to 15 kA·m-1 at 360 kHz for 10 min. For 
experimental temperature profiles to measure temperature elevation near the edge, 
composite scaffolds were placed in a 1.5 mL microcentrifuge tube with 1 mL of 
ultrasound gel. A type T thermocouple was placed 1.85 mm (close to the far edge of the 
scaffold) from the center of the scaffold to record the temperature rise within the tissue-
laden composite scaffold, which was treated for 4 minutes at 15 kA·m-1. For ex vivo 
tissue-laden scaffold heating studies, harvested scaffolds were used for measuring 
temperature profiles and cell viability. For ex vivo viability studies, tissue-laden scaffolds 
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were placed in 1 mL of phosphate-buffered saline (PBS) and treated for 10 minutes at 15 
kA·m-1. To account for the self-heating of the thermocouple in the oscillating magnetic 
field, the average dynamic temperature rise of thermocouple-only samples at each 
respective magnetic field strength, were subtracted from dynamic temperature rise 
profiles. 
 
For in vivo tissue-laden scaffold heating studies, due to size limitations of the animal 
body and coil dimensions, the implanted PCL-Al scaffold could not be placed in the 
center of the radiofrequency coil. To ensure a field strength of 15 kA·m-1 at the scaffold 
location, the center of the radiofrequency coil was set to 20 kA·m-1 and placed 9.25 mm 
above the implant site. FLIR E30 and FLIR A300 IR-cameras (FLIR Systems Inc.) were 
used to capture infrared (IR) images before and during 10-minute treatment. An in vivo 
heating profile was generated by analyzing the average temperature values in a ~5 mm 
diameter circular region encompassing the implanted scaffold in the IR video during 
treatment using ThermaCAM Researcher Professional 2.10 software (FLIR Systems 
Inc.). To evaluate the acute effect of treatment, scaffolds were harvested immediately 
after treatment to assess cellular viability. For chronic effects of thermal injury, mice 
were allowed to recover for three days, after which scaffolds were harvested and placed 
in formalin for histological analysis. Day three was chosen for this analysis in accordance 
with previous literature demonstrating that chronic effects of thermal therapy can be 
detected as early as three days after treatment [88, 89]. 
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Viability assay 
The viability of cells in tissue-laden scaffolds was determined by treating the cells with 
cell viability reagent WST-1 (Takara Bio). Scaffolds were transferred to 500 µL of fresh 
media (DMEM containing 10% fetal bovine serum, 1% L-glutamine, and 1% penicillin-
streptomycin; Thermo Fisher Scientific). Microscissors were used to mince the scaffolds 
into small pieces. 50 µL of WST-1 reagent was added to each sample and incubated at 37 
ºC for 2 hours.  Media samples were used as a negative control for background 
measurement, and 70% ethanol treatment of tissue-laden scaffolds was performed as a 
control for total cell death. For ethanol treatment, tissue-laden scaffolds were minced in 
500 µL of 70% ethanol and incubated on ice for 1 hour. Following ethanol incubation, 
the samples were centrifuged at 14,000 x g for 5 minutes, and the supernatant was 
replaced with 500 µL of fresh media prior to addition of the WST-1 reagent. After WST-
1 treatment, all samples were vortexed and centrifuged at 14,000 x g for 5 minutes. 400 
µL of sample was filtered through a 70 µm filter. Triplicates of 100 µL per sample were 
transferred to a 96-well plate. The absorbance of each well was measured at a wavelength 
of 440 nm with a Synergy H1 microplate reader (BioTek Instruments). 
 
qRT-PCR analysis of tissue-laden scaffolds from tumor-bearing mice 
Female 15-week-old BALB/c mice were inoculated with two million 4T1 breast cancer 
cells (ATCC CRL-2539) in a volume of 50 µL PBS in the number four right mammary 
fat pad. For tumor-free controls, mice received an injection of 50 µL PBS. One week 
post-inoculation, two scaffolds of the same type (PCL or PCL-Al) were implanted in the 
subcutaneous space. Tumors and scaffolds were harvested four weeks post-inoculation 
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and immediately snap frozen in liquid nitrogen and stored at -80 ºC for further RNA 
extraction. For RNA extraction, samples were placed in RLT buffer (Qiagen) with 1% β-
mercaptoethanol (Sigma-Aldrich) and homogenized at 10,000 rpm for 20 seconds on ice. 
To minimize the risk of cross-contamination between samples, after homogenization of 
each sample the homogenizer was washed with 3 rounds of Type 1 water, 2 rounds of 
70% ethanol, and 2 rounds of 100% ethanol, followed by a wash with ELIMINase 
(Thermo Fisher Scientific) and then 4 rounds of Type 1 water washes before running the 
next sample. Total RNA extraction was then performed using the RNeasy Mini Kit 
(Qiagen) following the manufacturer’s instructions. cDNA synthesis was performed with 
1 µg of total RNA for each sample using the Omniscript RT Kit (Qiagen), and qRT-PCR 
reactions were performed with 1 µL of cDNA, iTaq Universal SYBR Green Supermix 
(BioRad), and the gene-specific forward primer (250 nM) and reverse primer (250 nM). 
The qRT-PCR was performed using a CFX Connect Real-Time PCR Detection System 
(BioRad). Primers for GAPDH were obtained from the literature [90] and the remaining 
were obtained from PrimerBank (https://pga.mgh.harvard.edu/primerbank/). The primers 
used in these studies are summarized in Table 2-1. 
Table 2-1. Primer sequences used for qRT-PCR analysis. 
Gene Forward (5’-3’) Reverse (5’-3’) 
GAPDH CAATGTGTCCGTCGTGGA GATGCCTGCTTCACCACC 
FTH1 CAAGTGCGCCAGAACTACCA GCCACATCATCTCGGTCAAAA 
SPP1 AGCAAGAAACTCTTCCAAGCAA GTGAGATTCGTCAGATTCATCCG 
LYZ2 ATGGAATGGCTGGCTACTATGG ACCAGTATCGGCTATTGATCTGA 
PABPC1 CAAGCCAGTACGCATCATGTG TGCTTCCTGTGTTTCAAAGTGT 
EPCAM GCGGCTCAGAGAGACTGTG CCAAGCATTTAGACGCCAGTTT 
LCN2 TGGCCCTGAGTGTCATGTG CTCTTGTAGCTCATAGATGGTGC 
APOE CTGACAGGATGCCTAGCCG CGCAGGTAATCCCAGAAGC 
MT2 GCCTGCAAATGCAAACAATGC AGCTGCACTTGTCGGAAGC 
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Statistical analysis 
Data are presented as the mean ± standard deviation (SD), and p-values were determined 
using an unpaired Student’s t-test. For qRT-PCR studies, p-values were determined using 
a two-way analysis of variance (ANOVA) with a Tukey post hoc test. 
 
2.3 Results and discussion 
2.3.1 Characterizing heat generation from metal disks through electromagnetic 
induction 
Aluminum was chosen as the conducting material for the thermal seed as its low density 
and high malleability made it a versatile material for proof of principle studies. To 
evaluate the ability of 100 µm-thick aluminum disks to heat in response to the presence of 
an oscillating magnetic field, aluminum disks of various diameters (Fig. 2-1A) were 
submerged in water and placed in a radiofrequency coil, and an oscillating magnetic field 
at 15 kA·m-1 at 360 kHz was applied. As the disk diameter increased from 1.13 ± 0.05 
mm to 1.90 ± 0.04 mm, the temperature elevation achieved from the surface of the disk 
increased from 19 ± 2 ºC to 58 ± 4 ºC, indicating a positive correlation between disk 
diameter and temperature elevation (Fig. 2-1B). With the disk diameter fixed at 1.70 ± 
0.04 mm, the temperature elevation could also be modulated at a fixed frequency of 360 
kHz by increasing the magnetic field strength, resulting in temperature elevations from 5 
± 1 ºC at 5 kA·m-1 to 56 ± 4 ºC at 20 kA·m-1 (Fig. 2-1C). The type of metal used also 
affected its response to the magnetic field, with 1.68 ± 0.07 mm diameter copper disks 
generating a temperature elevation of 43 ± 3 ºC, in comparison to 47 ± 3 ºC for 1.70 ± 
0.04 mm diameter aluminum disks (Fig. 2-1D). These results are consistent with previous 
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work by Stauffer et al. [87] that shows power absorption of a conducting disk is based on 
radius, conductivity, and magnetic field strength. 
 
 
Figure 2-1. Metal disks show tunable heating response under alternating magnetic field. (A) 
100 µm thick, Al disks of varying diameters from left to right: 1.13 mm, 1.49 mm, 1.70 mm, and 
1.90 mm. Scale bar indicates 1 mm. (B-D) Temperature elevation of metal disks following 15 
minute exposure to magnetic field at 360 kHz for Al disks of varying sizes at 15 kA·m-1 (B), for 
1.7 mm Al disks at increasing magnetic field strengths (C), and for 1.7 mm disks with different 
metal composition at 15 kA·m-1 (D). (*) P < 0.01 compared to Al. Temperature data is mean ± 
SD, n = 8; disk diameter data is mean ± SD, n = 10. 
 
Heat generation is also directly related to skin depth (µm), δ, of the thermal seed [87]: 
! =  1!"#$  (2-1) 
where µ, σ, and f are relative permeability (dimensionless), electrical conductivity (Ω-1·m-
1), and coil frequency (MHz), respectively. Skin depth is an important design parameter 
as the current does not flow homogeneously through a conductor, but is confined near the 
surface. The skin depth is the distance from the surface which contains ~64% of the 
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current and 80% of the power, and thus 99% of the current flows within a layer four 
times the skin depth from the surface. Therefore, given our field orientation, to achieve 
the maximal heating potential the radius of the disk must be at least 4 times the skin 
depth. Based on the skin depths of aluminum and copper (Table 2-2), the disk radii 
should be at least 548 µm and 436 µm for aluminum and copper, respectively, for an 
alternating field resonating at 360 kHz. Thus, the 1.70 ± 0.04 mm aluminum disks were 
chosen for the remaining proof of concept studies, as they meet the thermal seed skin 
depth design requirements and are able to generate sufficient temperature elevations for 
rapid high-temperature thermal ablation. 
 
Table 2-2. Skin depth of aluminum and copper at a frequency of 360 kHz. 
 
 
 
 
 
2.3.2 Composite scaffold fabrication and biocompatibility 
Microporous polymer scaffolds composed of PCL, a slow-degrading biocompatible 
material, have previously been shown to recruit metastatic cancer cells in vivo [41]. In 
order to enable non-invasive application of focal hyperthermia to metastatic cells 
potentially captured by the scaffolds, 1.70 ± 0.04 mm aluminum disks were incorporated 
into the center of the polymer scaffolds. While induction heating in an alternating 
magnetic field is also possible with biocompatible metals, such as titanium or stainless 
steel, these metals are less malleable and more difficult to process. However, these 
options could be explored for clinical applications. Since aluminum is not biocompatible, 
the disks were first coated with a PCL film (Fig. 2-2A). To measure the thickness of the 
Material Relative Permeability (µ) Conductivity (σ) Skin Depth (δ) 
Aluminum 1.00 3.766·107 S·m-1 137 µm 
Copper 1.00 5.959·107 S·m-1 109 µm 
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film, it was partially delaminated (Fig. 2-2B). Profilometer measurements across the 
center of the polymer film-aluminum interface demonstrated a film thickness of 18.6 ± 
12.4 µm (Fig. 2-2C, D). The stability of the films was evaluated by submerging coated 
disks in PBS at 37 ºC for 31 days, at which point the measured film thickness, 17.4 ± 
10.9 µm, was not statistically different than the thickness of the Day 0 control (Fig. 2-
2D). Film thickness on the Al disk was also not affected by heating at 15 kA·m-1 and 360 
kHz for 10 min, as the resulting post-heating film thickness of 21.6 ± 7.1 µm was not 
statistically different from the non-treated control (Fig. 2-2D). 
 
 
Figure 2-2. Stability of biocompatible PCL coating on Al disks. (A) Image of uncoated Al disk 
(left) and PCL coated Al disk (right). Scale bar indicates 500 µm. (B) Image of PCL coated Al 
after being partially delaminated for film thickness measurements. Scale bar indicates 500 µm. 
(C) Representative profilometer scan across middle of partially delaminated disk showing step 
change from polymer coating to exposed metal. Arrow represents the value used to quantify 
polymer film thickness. (D) Film thickness of untreated coating (control), after treatment in PBS 
at 37 ºC for 31 days, and after heat treatment at 15 kA·m-1 and 360 kHz, for 10 min. No 
statistically significant differences were observed. Film thickness data is mean ± SD, n ≥ 8. 
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Previous reports have shown that polymer coatings on metal objects have improved 
biocompatibility in stents and dental implants [91, 92]. In one particular study, SaOS-2 
(human osteosarcoma) cell proliferation was vastly improved on magnesium disks 
containing PCL coatings ranging from 300 nm to 1 µm in thickness [93]. Another study 
showed no inhibition of L929 fibroblast growth after direct contact with nickel-titanium 
stents coated with a 400 nm thick coating of poly(2-chloroparaxylylene) [94]. Given 
these findings, the PCL film thickness achieved on our aluminum disks should render 
them biocompatible. A simple dip coating method was used to coat the aluminum disks 
with PCL, similar to other reports on polymer coating of metal stents [95, 96]. More 
sophisticated techniques have used chemical vapor deposition polymerization to grow 
polymer films with greater control of thickness and consistency [94], but for our 
purposes, dip coating accomplished the goal of completely coating the aluminum disk 
quickly with sufficient thickness to ensure biocompatibility. 
 
To incorporate the PCL-coated aluminum disks into microporous scaffolds, each disk 
was layered between two mixtures of PCL microparticles and 250-425 µm salt particles 
and pressed in a 5 mm die. The pressed composite material was then gas foamed and 
leached with water, resulting in a porous composite PCL-Al scaffold (Fig. 2-3). PCL-Al 
scaffolds were implanted subcutaneously in BALB/c mice and harvested 3-4 weeks later 
to evaluate scaffold biocompatibility by histology. H&E stained sections showed no signs 
of cytotoxicity in PCL-Al scaffolds as compared to PCL scaffolds, with PCL (Fig. 2-4A) 
and PCL-Al (Fig. 2-4B) tissue-laden scaffolds showing no statistical difference in the 
density of multinucleated cells, fibroblasts, new blood vessel formation, and 
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inflammatory infiltrates by pathological scoring (Table 2-3). These data demonstrate that 
the PCL-Al composite scaffolds are as biocompatible as unmodified PCL scaffolds in 
vivo. 
 
Figure 2-3. Fabrication of PCL-Al composite scaffolds. A PCL coated, 1.70 mm aluminum 
disk is layered in between two mixtures of PCL microparticles and sieved salt particles within a 
steel die and pressed. The pressed composite is then gas foamed to fuse polymer microparticles, 
after which the salt particles are leached out in water. 
 
 
Figure 2-4. Histological analysis of implanted composite PCL-Al scaffolds. Tissue-laden 
scaffolds harvested 3-4 weeks post-implantation from the subcutaneous space. Hematoxylin and 
eosin stained sections of PCL (A) and PCL-Al (B) scaffolds. Scale bar indicates 200 µm. 
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Table 2-3. Pathologist scoring of tissue-laden composite scaffolds. Density of multinucleated 
cells, fibroblasts, new blood vessel formation, and inflammatory infiltrate were analyzed in a 
blind study (n = 3).  
Density of Scaffold 
Type 
Average Scoring 
(0-3) 
Standard 
Deviation 
Multinucleated Cell PCL 2.3 0.6 PCL-Al 1.7 0.9 
Fibroblast PCL 2.4 0.5 PCL-Al 1.8 1.1 
New Blood Vessel 
Formation 
PCL 2.3 0.3 
PCL-Al 1.9 1.0 
Inflammatory 
Infiltrate 
PCL 2.6 0.2 
PCL-Al 1.9 0.5 
 
Composite PCL-Al scaffolds were also evaluated to verify that the ability to recruit 
metastatic breast cancer cells was not affected by the presence of the metal disk. To 
evaluate cancer cell recruitment to the scaffolds, a qRT-PCR approach developed for 
identifying melanoma cells [97] was modified to identify and evaluate genes highly 
expressed in 4T1 breast tumors. Eight genes (FTH1, SPP1, LYZ2, PABPC1, EPCAM, 
LCN2, APOE, and MT2) were selected as potentially highly expressed based on 
previously published microarray data (GSE64193) of harvested 4T1 tumors [98]. Further 
qRT-PCR analysis revealed that of these genes, FTH1, APOE, and MT2, were 
consistently highly expressed, as evidenced by low relative expression to the GAPDH 
reference gene, in two 4T1 primary tumors from our mouse model (Fig. 2-5A). MT2 was 
selected to evaluate the presence of metastatic cells within the implanted scaffolds, as of 
the three genes highly expressed in 4T1 tumors, MT2 exhibited the lowest expression in 
subcutaneous scaffolds from tumor-free mice (Fig. 2-5B). Both PCL and PCL-Al 
scaffolds exhibited statistically higher expression of MT2 compared to their respective 
control scaffolds from tumor-free mice, which indicates the presence of metastatic cells 
(Fig. 2-5C). Additionally, there was no significant difference in MT2 expression between 
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PCL and PCL-Al scaffolds in tumor-bearing mice (Fig. 2-5C). These results demonstrate 
that the ability of PCL scaffolds to recruit 4T1 tumor cells is unaffected by the addition of 
a metal disk to form the composite PCL-Al scaffold. 
 
 
Figure 2-5: In vivo capture of metastatic cancer cells to composite scaffolds. (A) qRT-PCR 
analysis of 4T1 primary tumors, PT1 and PT2, to isolate high expressed genes. (B) Relative 
expression (CtGENE – CtGAPDH) is mean SD. Gene expression analysis of PCL scaffolds from 
tumor-free mice. Relative expression (CtGENE – CtGAPDH) is mean ± SD, n = 4. (C) Comparison of 
MT2 relative expression in PCL and PCL-Al scaffolds from mice with either PBS only or 4T1 
inoculations. Relative expression (CtGENE – CtGAPDH) is mean ± SD. 
 
 35 
2.3.3 Ex vivo radiofrequency treatment of tissue-laden scaffolds results in cellular 
destruction 
Since the goal was destroy cells infiltrating the scaffold through thermal ablation, the 
capability of the embedded disk to deliver a sufficient temperature rise for ablation in 
tissue-laden scaffolds was tested. PCL-Al composite scaffolds were implanted in the 
subcutaneous space and harvested a few weeks later. These tissue-laden composite 
scaffolds were treated for 4 minutes at 15 kA·m-1 and 360 kHz, and the temperature 
elevation at the far edge of the scaffold, where the lowest amount of heating is expected 
as this position is furthest away from the thermal seed, was 26 ± 4 ºC (Fig. 2-6A), which 
is sufficient for thermal ablation. For evaluation of cell death, treatment time was 
increased to 10 minutes. To evaluate the degree of cell damage within the scaffolds, 
tissue-laden PLC and PCL-Al scaffolds were treated for 10 minutes at 15 kA·m-1 and 360 
kHz, and cellular viability within the scaffold was measured using a WST-1 assay (Fig. 
2-6B). As expected, untreated PCL scaffolds, treated PCL scaffolds and untreated PCL-
Al scaffolds displayed significantly higher cellular viability than control scaffolds that 
were submerged in 70% ethanol to kill the cells (negative control), since the thermal 
injury requires both electromagnetic induction and the thermal seed. Consequently, 
treated PCL-Al scaffold viability was substantially lower than that of untreated PCL or 
PCL-Al scaffolds or treated PCL scaffolds and showed no statistical difference with the 
70% ethanol control. Resulting tissue damage following treatment of PCL (Fig. 2-6C) 
and PCL-Al (Fig. 2-6D) scaffolds was also evaluated by histology. H&E stained sections 
of treated PCL scaffolds showed no negative effects from the oscillating magnetic field 
(Fig. 2-6C). Conversely, in treated tissue-laden PCL-Al scaffolds, cells exhibited central 
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bleeding from the induced thermal ablation (Fig. 2-6D). For verification that the chosen 
treatment conditions could kill breast cancer cells, 4T1 cells were encapsulated in 
Matrigel surrounding a 1.70 mm Al disk. Using the same magnetic field strength, 
frequency, and duration as in the treatment of tissue-laden PCL-Al scaffolds, 4T1 cancer 
cells were successfully ablated, as evidenced by a substantial decrease in viability (Fig. 2-
7). Taken together, these findings show that induced focal thermal ablation can 
effectively kill cells in the scaffold ex vivo and these parameters can also be applied to 
kill breast cancer cells in vitro. 
 
 
Figure 2-6. Ex vivo radiofrequency treatment ablates tissue-laden composite scaffolds. (A) 
Experimental temperature measurements at 1.85 mm radially from the center of the disk, near the 
edge of the scaffold, at 15 kA·m-1 and 360 kHz. Temperature data is mean ± SD, n = 4. (B) 
Viability assay (WST-1) of cells in tissue-laden scaffolds with and without ex vivo treatment for 
10 min at 15 kA·m-1 and 360 kHz. Black dashed line indicates background signal from no 
scaffold control. (*) P < 0.05 compared to 70% ethanol. Viability data is mean ± SD, n ≥ 4. (C, 
D) H&E stained sections of tissue-laden PCL (C) and PCL-Al (D) scaffolds following ex vivo 
treatment. Scale bar indicates 50 µm. 
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Figure 2-7. In vitro ablation of 4T1 cancer cells by induction heating. WST-1 viability assay 
performed on 4T1 cells encapsulated in Matrigel surrounding a 1.70 mm Al disk before and after 
treatment with an oscillating magnetic field at 15 kA·m-1 at 360 kHz for 10 min. As a positive 
control for cell death, samples treated with 70% ethanol were evaluated. (*) P < 0.001 compared 
to no treatment. Viability data is mean ± SD, n  = 3. 
 
2.3.4 Non-invasive, induced focal hyperthermia ablates tissue-laden composite 
scaffolds in vivo 
In order to test the clinical relevance of our system by including the effects of blood 
perfusion, we applied our system to an in vivo model. One PCL-Al and one PCL scaffold 
were implanted in the subcutaneous space of a BALB/c mouse. After at least 3 weeks to 
allow for host integration of the scaffolds, the radiofrequency coil was placed over the 
implanted PCL-Al scaffold. Due to physical constraints of the coil diameter and the size 
of the mouse, the implanted PCL-Al scaffold was outside the center of the coil where the 
magnetic field is homogeneous, as magnetic field strength drops with axial distance away 
from the center. Thus, to achieve the desired 15 kA·m-1 field strength at the location of 
the scaffold, the field strength in the center of the coil was increased to 20 kA·m-1 and the 
implanted scaffold was arranged 9.25 mm below the center of the coil. IR images before 
(Fig. 2-8A) and during (Fig. 2-8B) treatment showed distinct localized heating of the 
composite scaffold upon treatment. Analysis of IR video revealed that the temperature 
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elevation achieved during treatment of implanted PCL-Al scaffolds, 26 ± 6 ºC (Fig. 2-
8C), matched that of previous ex vivo results near the edge of the scaffold, 26 ± 4 ºC (Fig. 
2-6A), validating that positioning of the implanted scaffold 9.25 mm below the coil set to 
20 kA·m-1 achieves same heating profile as in the center of the coil at 15 kA·m-1. Acute 
effects of treatment resulted in a significant drop in 440 nm absorbance in treated PCL-Al 
scaffolds in comparison to the internal PCL controls using a WST-1 viability assay (Fig. 
2-8D), indicating significant cell death in the treated PCL-Al scaffolds. To study chronic 
effects from the thermal ablation treatment, scaffolds were harvested three days following 
treatment for histological analysis. Nearby PCL scaffolds did not show any sign of 
cellular damage (Fig. 2-8E), whereas treated PCL-Al scaffold showed areas of tissue 
necrosis (Fig. 2-8F) by H&E. Previous studies report similar chronic effects after focal 
treatment, observing tissue necrosis as early as three days post-treatment in rat livers 
treated with a laser [89] and in LNCaP tumors treated with cryosurgery [88]. These 
findings indicate that these composite scaffolds can be used to kill cells within the 
scaffold through non-invasive, focal hyperthermia in vivo. 
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Figure 2-8. Induced focal hyperthermia ablates composite scaffolds in vivo. (A,B) IR camera 
images before (A) and during (B) treatment show localized heating of the composite scaffold. (C) 
Temperature of PCL-Al scaffold as a function of time during in vivo treatment, obtained from IR 
video analysis. Temperature data is mean ± SD, n = 3. (D) Viability assay (WST-1) of treated 
PCL-Al and PCL internal control immediately after treatment. (*) P < 0.001 compared to PCL. 
Viability data is mean ± SD, n = 3. (E, F) H&E and stained sections of tissue-laden PCL (E) 
composite PCL-Al (F) scaffolds three days post-treatment. Examples of necrotic areas are 
outlined by black circles. Scale bar indicates 50 µm. 
 
2.4 Conclusions 
The purpose of this study was to adapt a microporous polymer scaffold, which has 
previously been shown to recruit metastatic cells, for application of non-invasive focal 
hyperthermia. This was accomplished by using a conductive aluminum disk as a thermal 
seed. The heat generation of the disk could be tuned by changing disk diameter, magnetic 
field strength, and type of metal. Microporous composite PCL scaffolds with a centrally 
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located aluminum disk integrated successfully with host tissue after subcutaneous 
implantation. Experimental induction heating studies confirmed that tissue-laden 
composite scaffolds were capable of reaching the necessary temperatures for high-
temperature hyperthermia. This resulted in the low cellular viability following treatment 
of ex vivo tissue-laden composite scaffolds under electromagnetic induction. 
Additionally, the in vivo, non-invasive, induction heating of subcutaneously implanted 
composite scaffolds proved to be localized and effective at ablating the desired tissue. 
These results demonstrate the ability of composite PCL-Al scaffolds to non-invasively 
eliminate infiltrating cells in vivo. 
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Chapter 3: Engineered polymer scaffolds with integrated electrodes for near-
uniform electric field distribution during IRE treatment 
3.1 Introduction 
Focal therapies, such as cryoablation (Cryo) [56], thermal ablation (Heat) [55], and 
irreversible electroporation (IRE) [57], have been successful alternatives to surgical 
resection for treating solid tumors [99]. As with surgical resections, however, focal 
therapies may lead to recurrence at the treatment site as the therapy may fail to destroy 
the tumor entirely [100, 101]. Nevertheless, Cryo [81, 102-104], Heat [81, 105-107], or 
IRE [108] focal therapies offer an immunological advantage over surgical resections due 
to the tumor-specific antigens that are released from cancer cells into the local 
environment during treatment. These exposed antigens could be used as to trigger a 
systemic immune response against the cancer cells that are left behind from treatment and 
those that are disseminated throughout the body. Although such immune responses have 
been shown with focal therapy treatment alone [81], immunologic adjuvants, such as 
intradermal dendritic cell injection [104, 107] or anti-CTLA-4 immune checkpoint 
inhibitors [81, 103] are often used to stimulate a more robust anti-tumor response. The 
use of focal therapy, however, has yet to be applied to disseminated cancer cells. 
 
The use of tumor lysates as a vaccine has also been demonstrated with microporous 
polymer scaffolds. In one study, lysates generated from harvested melanoma tumors 
treated with Cryo were incorporated into polymer scaffolds and implanted in mice with 
an established melanoma primary tumor. Following implantation, the lysate-loaded 
scaffolds induced an anti-tumor response that caused a decrease in primary tumor growth 
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and an improvement in overall survival in comparison to mice receiving blank scaffolds 
[82]. This suggests that anti-tumor immunity could be achieved by using focal therapy in 
vivo to expose tumorigenic antigens found in cancer cells recruited to a polymeric 
scaffold. In addition, the scaffold could be further engineered to enhance local 
immunomodulation in combination with the focal ablation. In this chapter, Heat, Cryo 
and IRE were applied to scaffolds in vivo to demonstrate their ability to ablate tissue in 
this context. Since the quality of the antigen produced will likely differ based on the 
method of ablation, and IRE has shown promise in eliciting higher levels T cell activation 
at lower tumor cell numbers [109], the ability to modify scaffolds for more homogeneous 
application of IRE was investigated. 
 
3.2 Materials and methods 
PCL scaffold fabrication and implantation 
PCL microspheres were first prepared as previously described [41]. Briefly, a 6% (w/w) 
solution of PCL (DURECT; inherent viscosity = 0.65-0.85 dL·g-1) in dichloromethane 
was emulsified in a 10% (w/w) poly(vinyl alcohol) solution and homogenized at 10,000 
rpm for 1 minute. Microspheres were lyophilized for 48 hours. PCL microspheres and 
sieved sodium chloride particles (250-425 µm) were mixed in a 1:30 (w/w) ratio and the 
contents were pressed to 3,300 lb (~15 kN) for 45 seconds in a 5 mm steel die (Specac). 
The pressed disks were heated at 60 ºC for 5 minutes on each side followed by foaming at 
800 psig for ~24 hours, after which the gas was released at 17.5 CFH. After foaming, salt 
particles were removed by immersing the scaffolds in water for 90 minutes on a rocking 
platform. Scaffolds were sterilized by soaking in 70% ethanol, followed by rinsing with 
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sterile water and drying on a sterile gauze pad. Scaffolds were then stored at -80 ºC until 
further use. 
 
Animal studies were performed in accordance with institutional guidelines and protocols 
approved by the University of Minnesota Institutional Animal Care and Use Committee 
(IACUC). Female C57BL/6 mice were purchased from The Jackson Laboratory, and 
mice were 6-8 weeks of age at the time of surgery. Two scaffolds were implanted into the 
subcutaneous space of the upper dorsal region in each mouse. Focal therapy experiments 
on tissue-laden scaffolds were performed 3-4 weeks following implantation. 
 
In vivo focal ablation of PCL scaffolds 
In vivo Cryo [110, 111], Heat [110], and IRE [112, 113] procedures previously described 
were applied to implanted tissue-laden scaffolds. Cryo treatment was performed using a 
17-gauge IceSeed cryoablation needle (Galil Medical Inc.). A small incision was first 
made in the center of the implanted scaffold with an 18-gauge needle to allow insertion 
of the probe tip through the skin and scaffold. Probe tip temperature was set to –150 ºC, 
and freezing was performed conservatively under infrared thermographic guidance until 
the  –40 °C isotherm reached the edge of the scaffold. The probe was then removed, and 
the scaffold was then passively thawed to body temperature. For Heat treatment, a 1 mm 
diameter brass extension tip was fitted to a temperature-controlled soldering iron tip 
(RadioShack) set to 150 ºC. A small incision was first made in the center of the implanted 
scaffold with a 25-gauge needle to allow insertion of the probe tip through the skin and 
scaffold. The scaffold was heated conservatively under monitoring with an infrared 
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camera (FLIR Systems Inc.) until the 50 °C isotherm reached the visible edge of the 
scaffold. The tip was then removed, and the scaffold was passively cooled to body 
temperature. A pair of customized two-probe electrodes connected to an electrical pulse 
generator (BTX ECM 830, Harvard Apparatus) was utilized for IRE treatment. The probe 
comprises two needle-type electrodes, each with a conductive tip (i.e. exposed without 
insulation). The needle electrodes (OD = 0.7 mm) were fixed with a center-to-center 
distance of 4 mm. Each needle electrode was coated with an insulating layer of heat 
shrink tubing, leaving a 3 mm tip for treatment. For treating implanted scaffolds, a ~1 cm 
skin incision was made beside the scaffold for greater exposure. The needle electrodes 
were inserted directly to the scaffold such that the electrodes were diametrically opposed. 
The electrical pulse generator was set to 99 pulses at 1000 V with 100 µs pulse durations 
at 1 Hz. All scaffolds were harvested either immediately or 24 hours following treatment 
for WST-1 cell viability or histological analysis, respectively.  
 
Metal mesh fabrication and coating 
Sheet of 304 stainless steel #50 woven wire mesh (The Mesh Company Ltd.), 0.348 mm 
aperture with 0.16 mm wire diameter, were punched with a 3/16 inch die and flattened 
gently with a press to make ~5 mm-diameter metal mesh disks. A copper loop (~2-3 mm 
diameter) was connected to the edge of each mesh to facilitate connection to an electrical 
pulse generator. To coat the metal disks with a polymer film, disks were dipped once into 
either a 10%, 5%, or 2.5% (w/w) solution of PCL (DURECT; inherent viscosity = 0.65-
0.85 dL·g-1) in dichloromethane (Sigma). Coated disks were dried overnight at room 
temperature and ambient pressure.  
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Coating characterization 
To characterize the polymer coating thickness, coated disks were first cut in half and later 
embedded in epoxy. The cut plane was then polished using successive finer grades of 
silicon carbide paper on a metallographic polisher. A final polish was done with 1 µm 
diamond paste on a Buehler Minimet Polisher (Illinois Tool Works Inc.). Samples were 
then sputtered with 50 Å of carbon and visualized with a JOEL 6500 scanning electron 
microscope (JEOL USA Inc.). Coating thickness was then measured from acquired 
images using ImageJ. Images were taken of 5 independent disks, with 4 different 
locations imaged per disk. 3 measurements were taken along the film in each image. 
 
Composite scaffold fabrication 
To fabricate composite “PCL-IRE” scaffolds for more uniform IRE application than 
probe-based methods, the pressed polymer/salt disk generated using the method 
described above for PCL scaffold fabrication was placed in between two PCL-coated 
metal mesh disks prior to foaming. After foaming, salt particles were removed by 90-
minute incubation of the scaffolds in water on a rocking platform. PCL-IRE scaffolds 
were sterilized in 70% ethanol, rinsed with sterile water, dried on a sterile gauze pad, and 
stored at -80 ºC until further use. 
 
Resistivity measurements 
PCL scaffolds of varying thicknesses were fabricated for resistivity studies. For in vitro 
measurements, scaffolds loaded with 20 µL of 5 mg·mL-1 Matrigel (Corning) and for ex 
vivo measurements, tissue-laden scaffolds were harvested 4 weeks post-implantation. 
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Scaffolds were placed between two parallel plate electrodes connected to a PSM3750 
frequency response analyzer with the IAI2 impedance analysis attachment (Newtons4th 
Ltd.) for impedance measurements. Impedance of loaded scaffolds was measured at 
frequencies of 1 MHz to 10 Hz at 1 V alternating current. Total resistance of the 
scaffold/electrode system was taken from the real part of impedance at high frequency 
(~1 MHz). This model assumes the scaffold/electrode system responds linearly with the 
total resistance and applied voltage at very short time scales (i.e. at high frequency), as is 
standard for materials containing electrolytes [114, 115]. Total measured resistance, RT, is 
then expressed by the following formula: !! = !! + !!  (3-1) 
where RS is bulk resistance of scaffold (Ω) and RR is residual resistance (Ω) from contact 
resistance with scaffold and electrode and resistances from electrodes and impedance 
analyzer. A linear regression fit was performed on the plot of total resistance as a 
function of thickness for Matrigel-loaded scaffolds. Bulk resistivity of scaffold, ρ (Ω·cm), 
was calculated by the following expression: 
! = !!!! ⋅ 1 !"10 !!  (3-2) 
where RS is bulk resistance of scaffold (Ω), A is cross-sectional area of scaffold (mm2), 
and l is thickness of scaffold (mm). The bulk resistivity for Matrigel-loaded scaffolds was 
then calculated by multiplying the slope of the linear regression fit by the cross-sectional 
area of the scaffold. Due to the variability in diameter of harvested tissue-laden scaffolds, 
total resistance was plotted as a function of thickness divided by cross-sectional area, and 
bulk resistivity was then equal to the slope of the linear regression fit. 
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Modeling of electric field distribution from different electrode configurations 
The IRE electric field distributions in the scaffolds were modeled using COMSOL 
Multiphysics version 5.3a (COMSOL Inc.) for parallel plate, two-probe, and metal mesh 
geometries. 
 
Utilizing PCL-IRE scaffolds for ablation 
B16-F10 melanoma cancer cells (ATCC CRL-6475) were loaded onto polymer scaffolds 
for in vitro IRE treatment studies. B16-F10 cells were suspended in 5 mg·mL-1 Matrigel 
(Corning) at 50E6 cells·mL-1. PCL or composite PCL-IRE scaffolds were submerged in 
70% ethanol followed by two washes with culture media. Scaffolds were then partially 
dried on gauze pads for 5 minutes each side, and 20 µL of the Matrigel-B16-F10 was 
loaded into each scaffold followed by a 5-minute incubation at 37 ºC prior to IRE 
treatment. B16-F10 loaded PCL scaffolds were placed between two parallel plate 
electrodes connected to an electrical pulse generator (BTX ECM 830, Harvard 
Apparatus). For B16-F10 loaded composite PCL-IRE scaffolds, spring-loaded metal 
hooks (Minigrabber, Pomona Electronics) were attached to the copper loops on the metal 
meshes to connect PCL-IRE scaffolds to the electrical pulse generator. For in vivo 
treatment of tissue-laden scaffolds, a dorsal skin incision was made 3-4 weeks following 
implantation to expose copper loops for attachment through spring-loaded metal hooks. 
All cell-laden scaffolds were then treated at specified, calculated electric fields with 99 
pulses with 100 µs pulse duration at 1 Hz. Specified electric fields were calculated by 
dividing applied voltage by the thickness of the loaded scaffold. Following treatment, 
scaffolds were tested for cellular viability using the WST-1 assay. 
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WST-1 viability assay 
The viability of cells in tissue-laden or B16-F10 loaded scaffolds was determined by 
treating the cells with cell viability reagent WST-1 (Takara Bio). Harvested scaffolds 
were transferred to 500 µL of fresh media (DMEM containing 10% fetal bovine serum, 
1% L-glutamine, and 1% penicillin-streptomycin; Thermo Fisher Scientific). 
Microscissors were used to mince the scaffolds into small pieces. 50 µL of WST-1 
reagent was added to each sample and incubated at 37 ºC for 2 hours for tissue-laden and 
B16-F10 loaded PCL and PCL-IRE scaffolds. For the study involving tissue-laden 
composite PCL-IRE scaffolds, a 3.5-hour incubation was performed due to timing 
restrictions. A media sample was used as a negative control for background 
measurement. As negative controls for viable cells, tissue-laden scaffolds were treated 
with 70% ethanol and acellular, Matrigel-only scaffolds were used for in vivo focal 
therapy and in vitro IRE treatment, respectively. For ethanol treatment, tissue-laden 
scaffolds were minced in 500 µL of 70% ethanol and incubated on ice for 1 hour. 
Following ethanol incubation, the samples were centrifuged at 14,000 x g for 5 minutes, 
and the supernatant was replaced with 500 µL of fresh media prior to addition of 50 µL of 
WST-1 reagent. After WST-1 incubation, all samples were vortexed and centrifuged at 
14,000 x g for 5 minutes. 400 µL of supernatant was filtered through a 70 µm filter. 
Triplicates of 100 µL per sample were transferred to a 96-well plate. The absorbance of 
each well was measured at a wavelength of 440 nm with a Synergy H1 microplate reader 
(BioTek Instruments). 
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Tissue sectioning and histological analysis 
For histological analysis of ablation effects, tissue-laden PCL scaffolds were removed 
whole from the subcutaneous space 24 hours following Cryo, Heat, and IRE treatment. 
For histological analysis of the biocompatibility of PCL-IRE scaffolds, PCL or PCL-IRE 
scaffolds were removed from the subcutaneous space 3-4 weeks after implantation. The 
tissue-laden scaffolds were fixed in 10% buffered formalin, embedded in paraffin, and 
sectioned at 4 µm using an HM 315 microtome (Microm). For PCL-IRE scaffolds, metal 
mesh electrodes were removed from composite scaffolds prior fixation. Slides were 
stained with hematoxylin and eosin (H&E) or terminal dUTP nick-end labeling (TUNEL) 
for histological analysis. TUNEL staining was done using the ApopTag Peroxidase In 
Situ Apoptosis Detection Kit (MilliporeSigma) following the manufacturer’s instructions. 
Slides were imaged using an EVOS FL Auto Microscope (Thermo Fisher Scientific). 
 
Statistical analysis 
Data are presented as the mean ± standard deviation (SD), and p-values were determined 
using an unpaired Student’s t-test. 
 
3.3 Results and discussion 
3.3.1 In vivo application of focal therapy to tissue-laden scaffolds 
As a proof-of-principle that different modalities of focal therapy can be applied to kill 
cells within the scaffolds in vivo, PCL scaffolds were implanted into the dorsal, 
subcutaneous space of C57BL/6 mice. After 3-4 weeks to allow for tissue infiltration, 
scaffolds were then exposed to Cryo, Heat, or IRE treatment. Each focal therapy was 
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applied with an external applicator: a 1.5 mm wide cryoablation needle for Cryo, a 1 mm 
brass probe attached to an electric heater for Heat, and a two-probe electrode applicator 
with 4 mm spacing for IRE. The immediate effects on cellular viability within the 
scaffolds following these treatments were measured using a WST-1 assay (Fig. 3-1). 
Viability of cells within the scaffolds dropped by 98%, 89%, and 89% following Cryo, 
Heat, and IRE, respectively. Treatment with 70% ethanol was utilized as a control for 
complete killing of all cells within the tissue-laden scaffold. 
 
 
Figure 3-1. In vivo focal therapy applied to tissue-laden scaffolds causes loss of cellular 
viability. Viability assay (WST-1) of cells in tissue-laden PCL scaffolds harvested immediately 
following Heat, Cryo, and IRE treatment. (*) P < 0.001 compared to untreated samples. Viability 
data is mean ± SD, n ≥ 11. 
 
Cell death was further analyzed by TUNEL staining on histological sections of PCL 
scaffolds treated with focal therapy. TUNEL staining can be used to examine cell death 
by labeling cleaved DNA strands, as nuclear DNA fragmentation is a hallmark of cell 
death [116, 117]. To allow enough time for enzymatic degradation of nuclear DNA [116], 
 51 
scaffolds were harvested 24 hours following treatment. Fig. 3-2 shows sequential sections 
from scaffolds treated with Cryo, Heat, and IRE stained with H&E and TUNEL. All three 
treatments show elevated numbers of TUNEL-positive cells in comparison to the 
untreated scaffold. Taken together, these results show that various types of focal therapy 
can be applied to successfully ablate cells within tissue-laden scaffolds in vivo. 
 
 
Figure 3-2. In vivo histological analysis of cell death in treated tissue-laden scaffolds. Images 
of H&E (top row) and TUNEL (center and bottom row) staining of untreated tissue-laden PCL 
scaffolds (first column) or 24 hours after in vivo application of Cryo (second column), Heat (third 
column), and IRE (fourth column) treatment. Higher magnification of images of TUNEL images 
(bottom row). Scale bar indicates 50 µm. 
 
Although these results show that Cryo, Heat, and IRE focal therapies can kill cells 
recruited to polymer scaffolds in vivo, downstream immune activation can vary 
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depending on the type of focal therapy [81]. Differences might be attributed to how the 
therapy affects antigen release and structure. Collaborative work with the Shimizu and 
Bischof groups at the University of Minnesota has used B16-F10 murine melanoma as a 
cancer model to investigate how the release of tyrosinase-related protein-2, a melanoma 
specific antigen [118], from different focal therapy conditions affects T cell activation in 
vitro. Recent results have shown that B16-F10 cell lysates from IRE treatment produce 
the strongest T cell activation when compared to thermal and cryoablation [109]. Local 
application of IRE has also been demonstrated to induce systemic effects in vivo; IRE 
treatment of a subcutaneous kidney primary tumor led to a reduction or suppression of 
growth following a secondary tumor challenge [108]. Thus, we hypothesized that IRE 
could be used to ablate cancer cells in the scaffold to release tumor specific antigens and 
elicit a cancer specific immune response. For this study, B16-F10 cells were used to 
investigate necessary IRE parameters to ablate melanoma cells within PCL scaffolds. 
 
3.3.2 Determining IRE field parameters necessary to kill melanoma cells 
Since several parameters, such as electric field strength, number of pulses, pulse duration, 
and frequency, affect treatment efficacy of IRE, we evaluated the necessary conditions to 
kill B16-F10 murine melanoma cells in polymer scaffolds in vitro. Melanoma cells were 
suspended in Matrigel and loaded into PCL scaffolds, and these cell-laden scaffolds were 
then placed in between two parallel plate electrodes connected to a pulse generator (Fig. 
3-3A). This geometry was utilized so that application of a voltage drop across the plates 
would create a homogeneous electric field distribution throughout the scaffold and the 
strength of the electric field could be taken to be the applied voltage potential divided by 
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the gap between the plates [119]. The number of pulses and pulse duration were kept 
constant at 99 and 100 µs, respectively, because these parameters have been shown to be 
effective at killing LNCaP prostate cancer cells in suspension at low electric field 
strengths [120]. In order to determine the necessary electric field strength to kill B16-F10 
cells, B16-F10 loaded scaffolds were treated with electric field strengths ranging from 0 
V·cm-1 to 2000 V·cm-1, and viability was measured using the WST-1 assay (Fig. 3-3B). 
Compared to cells in untreated scaffolds, viability of cells in treated scaffolds dropped by 
33% and 94% at 500 and 1500 V·cm-1, respectively. Samples treated at 2000 V·cm-1 
showed no statistical difference compared to acellular control scaffolds. These results 
show similar trends as treated LNCaP prostate cancer cells in suspension: relatively high 
cellular viability at 500 V·cm-1 or below and near complete cell death at 1500 V·cm-1 or 
higher. These electric field parameter values have also been effective for soft tissue 
ablation in vivo, as 1000 – 2500 V·cm-1 has commonly been used [120]. The results 
suggest that electric fields of at least 1500 V·cm-1 would be sufficient to treat melanoma 
cells that have metastasized to the scaffold. Although parallel plate electrodes create a 
homogeneous electric field distribution throughout the scaffold, this electrode geometry 
may not be directly integrated with the scaffold as solid plates would render the scaffold 
pores inaccessible for the majority of the scaffold surface, which could inhibit cell 
infiltration and proper integration and vascularization to the scaffolds, therefore impeding 
cancer cell recruitment. Other electrode geometries will therefore be investigated to apply 
lethal IRE parameters throughout the scaffold. 
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Figure 3-3. Characterizing IRE parameters necessary to ablate melanoma cells using 
parallel plate geometry in vitro. (A) Schematic of in vitro set up: B16 melanoma cells are 
suspended in Matrigel and loaded into a PCL scaffold; the scaffold is then placed in between 
parallel plate electrodes, which are connected to a pulse generator. (B) Viability as determined by 
WST-1 assay of B16 cells from cell-laden scaffolds at varying electric field strengths after 99 
pulses with 100 µs pulse duration at 1 Hz. (*) P < 0.01 compared to untreated samples. Viability 
data is mean ± SD, n = 3. 
 
3.3.3 Modeling electric field distribution with different electrode geometries 
Modern applications of IRE involve the use of two or four cylindrical probes to deliver 
treatment to the tumor. These probes are designed to be minimally invasive, but unlike 
parallel plate electrodes, cylindrical probe electrodes deliver a heterogeneous electric 
field, with the strength of the field decreasing with an r–1 dependence, where r is the 
distance from the probe [121]. Achieving a more uniform electric field within the area of 
treatment would allow for better control over the quality of the tumor-specific antigen 
released, impacting the downstream immune response. In the context of the scaffold, 
metal meshes could be utilized in place of solid plates to allow for cell infiltration while 
potentially delivering a more homogeneous electric field than is achievable by cylindrical 
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probes. To determine whether this alternative electrode design could be a substitute for 
the parallel plate electrodes, we modeled the spatial electric field distribution for three 
different electrode geometries: parallel plate, two-probe, and metal mesh electrodes. 
 
In order to correctly model the expected electric field distribution, the resistivity of the in 
vitro Matrigel-loaded scaffold was evaluated. Due to the low concentration of B16-F10 
cells loaded within the scaffold, the resistivity of Matrigel-only scaffolds were used a 
model to represent the in vitro system. Resistivity was evaluated by measuring the overall 
resistance of Matrigel-loaded scaffolds of varying thicknesses. By plotting the overall 
resistance as a function of scaffold thickness, the resistivity of the Matrigel-loaded 
scaffold, 228 Ω·cm, was calculated from the slope of the linear regression fit across the 
data, in which the slope represents the resistance normalized by the scaffold thickness 
(Fig. 3-4A). To determine the resistivity of PCL scaffolds with a microenvironment 
resembling what would be in vivo, PCL scaffolds were implanted in the dorsal 
subcutaneous space in mice and harvested 3-4 weeks later to allow for host cell 
infiltration into the scaffold. Due to the variable diameter of harvested scaffolds, overall 
resistance was plotted as a function of scaffold thickness normalized to cross-sectional 
area, where the slope of the linear regression fit was then equal to the resistivity of tissue-
laden scaffolds, 312 Ω·cm (Fig. 3-4B). For both Matrigel-loaded and harvested tissue-
laden scaffolds, calculated resistivity values were within the range of measured values in 
other soft tissues, such as the kidney, muscle, and thyroid [122]. For proof-of-concept, 
resistivity of Matrigel-loaded scaffolds was then utilized to determine the effect of 
electrode configuration on expected electric field distribution. Calculated resistivity value 
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for tissue-laden scaffolds could be used in the future to further refine model expectations 
in complex animal studies. 
 
 
Figure 3-4. Analysis of resistivity of Matrigel-loaded and tissue-laden PCL scaffolds. (A) 
Overall resistance of Matrigel-loaded scaffold measured in parallel plate configuration as a 
function of scaffold thickness. (B) Overall resistance of tissue-laden PCL scaffold measured in 
parallel plate configuration as a function thickness divided by cross-sectional area. Each scaffold 
is represented as an open circle from an average of 3 technical replicates per scaffold. Four 
different scaffold heights were evaluated, with four scaffolds per height tested for Matrigel-
loaded scaffolds and three scaffolds per height for tissue-laden scaffolds. 
 
In collaboration with the Bischof group, the calculated resistivity for Matrigel-loaded 
scaffolds was then implemented into a COMSOL model to generate predicted electric 
field distributions for parallel plate, two-probe, and metal mesh electrode geometries. 
Electric field distribution throughout the scaffold for all geometries was graphed as a 
rectangular cross-section across the diameter and as a circular cross-section averaged 
across the thickness of the scaffold. As expected for parallel plate electrodes (Fig. 3-5A), 
the electric field distribution is uniform throughout the scaffold (Fig. 3-5D, G). However, 
the modeled distribution for the two-probe electrode geometry demonstrates that the 
electric field decays radially away from the electrodes (Fig. 3-5E, H). Since the scaffold 
thickness is much smaller than the length of the needle electrodes, the electric field 
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distribution does not vary along the height of the scaffold (Fig. 3-5E). The model was 
then applied to PCL scaffolds with a metal mesh electrode geometry (Fig. 3-5C). The 
rectangular cross-section (Fig. 3-5F) reveals that the electric field varies the most near the 
top and bottom of the scaffold, in proximity to the metal mesh, but the electric field is 
otherwise nearly uniform throughout most of the scaffold. The circular cross-section 
averaged throughout the thickness of the scaffold shows the relatively small impact of the 
metal mesh electrodes on the heterogeneity of the expected electric field distribution 
throughout the scaffold, as the distribution is nearly uniform (Fig 3-5I) and resembles that 
of a parallel plate geometry (Fig. 3-5G). 
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Figure 3-5. Predicted electric field distribution from parallel plate, two-probe, and metal 
mesh electrode geometries. (A-C) Schematics of parallel plate (A), two-probe electrode (B), and 
metal mesh (C) configurations with polymer scaffolds. (D-F) Rectangular cross-section of electric 
field distribution along diameter of scaffold using parallel plate (D), two-probe (E), and metal 
mesh (F) electrode geometries. (G-I) Circular cross-section of electric field distribution averaged 
across thickness of scaffold using parallel plate (G), two-probe (H), and metal mesh (I) electrode 
geometries. 
 
To further compare the electric field distribution between the three electrode geometries, 
the field strength field distribution across the scaffold volume was evaluated for each 
configuration. For quantitative comparison of electric field heterogeneity in each 
geometry, the simulation was constrained such that the average electric field strength 
across the scaffold for each electrode geometry was 2000 V·cm-1. When the simulation 
results for electric field strength were averaged across the scaffold geometry, as expected 
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the average was 2000 V·cm-1 for each geometry, but the two-probe electrode geometry 
had a larger standard deviation of 710 V·cm-1 compared to the metal mesh electrode, 310 
V·cm-1. The heterogeneity in electric field values were further analyzed by plotting the 
frequency distribution of field strength values across the scaffold volume for parallel 
plate (Fig. 3-6B), two-probe (Fig. 3-6C), and metal mesh (Fig. 3-6D) electrode 
configurations. The distribution of the two-probe electrode geometry was the most 
heterogeneous, with only 26% of the volume centered around the 2000 V·cm-1 target 
value, in the range of 1750-2250 V·cm-1, while 87% of the scaffold volume in the metal 
mesh geometry was in the 1750-2250 V·cm-1 range. As a consequence of the near-
uniform distribution from the metal mesh electrode configurations, 97% of the scaffold 
volume was at or above the 1500 V·cm-1 threshold needed to kill B16-F10 cells in vitro 
(Fig. 3-3B), compared to only 74% of the scaffold volume for the two-probe electrode 
geometry. The geometry of the metal mesh could be further optimized in the future to 
achieve a more uniform distribution using this modeling approach; however, this metal 
mesh geometry was tested for proof-of-principle demonstration that PCL scaffolds could 
be modified with built-in electrodes for more uniform IRE treatment than that of 
conventional approaches. A more uniform IRE treatment could lead for better control of 
antigen release and presentation for downstream immunotherapy applications. 
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Figure 3-6. Evaluating spatial electric field distribution across different electrode 
geometries. (A) Average electric field strength across scaffold volume for parallel plate, two-
probe, and metal mesh electrode geometries using COMSOL model. Error bars indicate SD. (B-
D) Frequency distribution histograms for simulated electric field values throughout the scaffold 
for parallel plate (B), two-probe (C), and metal mesh (D) electrode geometries. 
 
3.3.4 Fabricating IRE composite scaffolds 
In order to fabricate scaffolds with built-in electrodes for a near-uniform IRE treatment, 
metal meshes made of stainless steel were attached to the top and bottom faces of the 
scaffold. To aid in connecting metal meshes to electrical pulse generator, a copper loop 
was attached to each metal mesh. Since neither the alloy of stainless steel nor copper used 
are biocompatible, the mesh assembly was first coated in a film of PCL, using the same 
dip coating procedure described in Chapter 2, section 2.3.2. However, the procedure had 
to be modified because films of PCL were present within the pores of the mesh (Fig. 3-
7A, 10 % w/w), which would block cell infiltration. The presence of polymer within the 
pore may have been caused by PCL coming out of solution before the evaporation of 
organic solvent was able to destabilize the wetting of the pores. It was hypothesized that 
this effect could be limited by decreasing the concentration of PCL in the coating solution 
to allow dewetting of the organic solvent within the pores prior to PCL precipitation. As 
the concentration of PCL in the coating solution decreased from 10 to 2.5 %w/w, the 
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number of blocked pores also decreased (Fig. 3-7A). As no blocked pores were seen at 
2.5 %w/w PCL in dichloromethane (Fig. 3-7A), this solution was used as the coating 
solution for the meshes. Scanning electron microscopy images of cross sectional slices 
(Fig. 3-7B) demonstrated a film thickness of 2.40 ± 0.96 µm (Fig. 3-7C). As mentioned 
previously in Chapter 2, section 2.3.2, a PCL coating of 300 nm to 1 µm has been shown 
to be sufficient to ensure biocompatibility of metal objects [93]. Despite the variability in 
measured film thickness, the thinnest film measurement was above this threshold for 
biocompatibility (Fig. 3-7C). Coated meshes were placed on either side of a pressed 
PCL/salt disk and then gas foamed to fuse the polymer from the mesh and the scaffold 
together. The composite scaffold was then leached in water to remove the salt crystals 
(Fig. 3-7D, E). 
 
 
Figure 3-7. Characterization of PCL-coated mesh. (A) Optical image of scaffolds after dip 
coating in 10 %w/w (left), 5 %w/w (center), or 2.5 %w/w (right) PCL in dichloromethane. Scale 
bar indicates 1 mm. (B) Scanning electron micrograph of cross section of coated metal mesh, 
with section of PCL film outlined by white parallel lines between arrows. Scale bar indicates 10 
µm. (C) Measurement of PCL film thickness from electron micrographs. Each color represents an 
independent wire mesh (n = 5), and each dot represents the average of 3 measurements of 
different areas in one image. 4 separate locations were imaged per mesh. Film thickness is also 
shown as mean ± SD. (D, E) Optical images of composite PCL-IRE scaffolds from the top (D) 
and side (E). Scale bar indicates 1 mm. 
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To investigate biocompatibility of composite PCL-IRE scaffolds, PCL scaffolds with attached 
metal meshes were implanted subcutaneous in C57BL/6 mice. After 3-4 weeks, scaffolds were 
harvested and biocompatibility was analyzed through histology. H&E sections of regular PCL 
(Fig. 3-8A) and PCL-IRE (Fig. 3-8B) scaffolds show no noticeable signs of cytotoxicity from the 
addition of metal meshes. These results show that the modified PCL-IRE scaffolds are as 
biocompatible as regular PCL scaffolds. 
 
 
Figure 3-8. Histological analysis of implanted PCL-IRE scaffolds. Tissue-laden PCL scaffolds 
with (PCL-IRE) and without (PCL) metal mesh electrodes were harvested 3-4 weeks post-
implantation. (A, B) H&E stained sections of PCL (A) and PLC-IRE (B) scaffolds. Scale bar 
indicates 200 µm. 
 
3.3.5 Use of PCL-IRE composite scaffolds to kill melanoma cells in vitro 
To validate the ability of the composite scaffolds to kill melanoma cells under the same 
parameters as with the parallel plate configuration, B16-BL6 melanoma cells were 
suspended in Matrigel and loaded into the composite scaffolds. The two meshes were 
then connected to the electrical pulse generator and treated under the same voltage 
potential that generated a homogeneous 2000 V·cm-1 electric field strength under the 
parallel plate geometry. The resulting cellular viability is shown in Fig. 3-9. As seen 
previously with the parallel plate geometry, there was no statistical difference between 
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treated composite scaffolds and acellular composite scaffold controls. These findings 
show that fabricated PCL-IRE composite scaffolds can effectively kill melanoma cancer 
cells within the scaffold in vitro. 
 
 
Figure 3-9. In vitro B16 viability following treatment in PCL-IRE composite scaffold. 
Viability assay (WST-1) of PCL-IRE scaffolds containing B16 cells, without and with treatment 
at 2000 V·cm-1, or Matrigel only control. (*) P < 0.001 compared to untreated samples. Viability 
data is mean ± SD, n ≥ 4. 
 
3.3.6 Application of IRE to tissue-laden composite PCL-IRE scaffolds in vivo 
To test the feasibility of utilizing PCL-IRE scaffolds to treat infiltrating cells in vivo, 
PCL-IRE scaffolds were implanted in the subcutaneous space in C57BL/6 mice. After 3-
4 weeks to allow for host cell infiltration, a skin incision was made to expose the copper 
loops that are attached to metal meshes of the composite scaffolds. These copper loops 
were used to facilitate connection of PCL-IRE scaffolds to the electrical pulse generator. 
The same conditions used previously to treat melanoma cells in vitro, both with parallel 
plate and metal mesh geometries, were used to treat implanted, tissue-laden composite 
PCL-IRE scaffolds. Post-treatment viability of cells within scaffolds demonstrated that 
cells within 1 of the 4 treated scaffolds were completely killed (Fig. 3-10). The remaining 
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treated scaffolds resulted in either partial decrease in cell viability in comparison to no 
treatment controls or no decrease in viability. Further optimization is needed to 
understand why some scaffolds were ineffectively treated, but it could have occurred 
from endogenous tissue remaining on copper loops, thus inhibiting proper electrical 
contact to the instrument, and/or electrical current pathways through tissue adjacent to the 
scaffold reducing the voltage potential across the metal meshes. Nonetheless, PCL-IRE 
scaffolds with embedded metal mesh electrodes can be utilized to kill infiltrating cells 
from host through IRE in vivo. 
 
 
Figure 3-10. IRE treatment of implanted PCL-IRE scaffolds in vivo. Viability assay (WST-1) 
of untreated PCL-IRE scaffolds, treated PCL-IRE scaffolds, and control scaffolds in which cells 
were killed with 70% ethanol. Each bar represents an individual scaffold. Viability data for each 
individual scaffold is shown as mean ± SD of three technical replicates. 
 
3.4 Conclusions 
In summary, PCL scaffolds can be modified with metal mesh electrodes to generate 
electric fields that are more homogeneous than those generated using the traditional two-
probe geometry. In vitro studies determined that PCL-IRE scaffolds could kill embedded 
melanoma cells as effectively as parallel plate electrodes under the same applied voltage, 
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number of pulses, pulse duration, and frequency. Additionally, composite PCL-IRE 
scaffolds could be utilized for IRE treatment of infiltrating host cells in vivo, but further 
optimization is necessary to increase robustness of the treatment. Future studies will 
apply this technology to target disseminated melanoma cells for the potential release of 
melanoma-specific antigens for generation of a downstream cancer-specific immune 
response. 
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Chapter 4: Utilizing liposomes for inducible release upon irreversible 
electroporation 
4.1 Introduction 
In Chapter 3, PCL scaffolds were modified with metal meshes to create a semi-uniform 
electric field towards the goal of using irreversible electroporation (IRE) to ablate 
recruited cancer cells in such a manner that the tumor antigens released upon cell lysis 
could be utilized to induce an anti-cancer immune response. Although a systemic anti-
tumor immune response has been shown through the use of IRE alone [108], the 
associated immune activation from energy-based ablation is typically too weak for a 
robust response [104]. The use of adjuvants to stimulate the immune system in 
conjunction with focal therapy has been shown to improve anti-tumor immunity. 
Adjuvants such as intratumor injection of dendritic cells to aid in T cell activation [104], 
intraperitoneal injection of immune checkpoint inhibitors [81], and peritumoral injection 
of danger signals such as unmethylated CpG oligodeoxynucleotides (CpG-ODN) [123], 
which are typically found in bacteria, have previously been shown to assist in triggering 
an innate immune response [124]. 
 
Adjuvants might be especially necessary when targeting disseminated cancer cells in the 
scaffold because of the significantly smaller amount of antigen release in comparison to 
the release when treating a solid tumor. Although the scaffolds may be modified to attract 
more cancer cells [39], the increase may not be sufficient to incite a robust response. 
Modifying the scaffold to release immunostimulants upon application of focal therapy 
could modulate the local environment and boost the immune response to target 
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disseminated cancer cells. The incorporation of the adjuvants CpG-ODN and pro-
inflammatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) 
along with B16 tumor lysate into biodegradable polymer scaffolds implanted 
subcutaneously has been shown to repress primary tumor growth in immunocompetent 
mice [82]. This method, however, uses tumor lysate harvested from a solid tumor to 
introduce cancer-specific antigens to the scaffold, which may not be possible for cases 
involving non-resectable tumors or disseminated cancer cells. Additionally, the release 
from this system is correlated with the degradation of the polymer in the body [125]; with 
inducible release, the release of adjuvants can be controlled by a physical cue, such as pH 
[126], infrared light [127], heat [128], or an electric field [129]. Thus in theory, release of 
immunostimulants could be timed with IRE treatment of disseminated cancer cells at the 
scaffold to generate a stronger immune response. This chapter will focus on incorporating 
of inducible release mechanisms in the polymer scaffold upon IRE treatment. 
 
4.2 Materials and methods 
Scaffold fabrication 
To fabricate polymer scaffolds, PCL microspheres were first prepared as previously 
described [39]. Briefly, for PCL microspheres, a 6% (w/w) solution of PCL (DURECT; 
inherent viscosity = 0.65-0.85 dL·g-1) in dichloromethane was emulsified in a 10% (w/w) 
poly(vinyl alcohol) solution and homogenized at 10,000 rpm for 1 minute. Microspheres 
were lyophilized for 48 hours and then mixed with sieved sodium chloride particles (250-
425 µm) in a 1:30 (w/w) ratio. Microsphere/sodium chloride mixtures were pressed to 
3,300 lbs. (15 kN) for 45 seconds in a 5 mm steel die (Specac). Pressed disks were heated 
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at 60 ºC for 5 minutes on each side and then foamed at 800 psig for ~24 hours, after 
which the gas was released at 17.5 CFH. Salt particles were removed by immersing disks 
in water for 90 minutes on a rocking platform. Polymer scaffolds were sterilized by 
soaking in 70% ethanol, followed by rinsing with sterile water and drying on a sterile 
gauze pad. Scaffolds were then stored at -80 ºC until further use. 
 
Aminolysis of polymer scaffolds 
The aminolysis reaction with PCL scaffolds was adapted from Nisbet et al. [130]. PCL 
scaffolds were placed in a 0.05 M ethylenediamine (MilliporeSigma) in isopropyl alcohol 
(MilliporeSigma) and incubated at ambient pressure at either room temperature for 10 
minutes or at 37 ºC for 24 hours. Scaffolds were then rinsed three times with water, with 
a five-minute soak between each rinse followed by a final 1 hour soak prior to use.  
 
Primary amine characterization 
Primary amine functionalization of PCL scaffolds was characterized by fluorescence 
labeling using fluorescamine (MilliporeSigma). PCL scaffolds were placed in a 10 mM 
fluorescamine solution in acetone. Immediately after, an equal volume of borate buffer, 
pH 9, was added to the fluorescamine solution. After 10 minutes, scaffolds were rinsed 
three times with water, with a five-minute soak between each rinse. Scaffolds were 
imaged using an EVOS FL Auto Microscope (Thermo Fisher Scientific) equipped with 
357 nm/447 nm excitation/emission wavelength light filter. 
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Liposome formation 
Liposomes were prepared by the hydration of lipid thin-films followed by extrusion. 
Briefly, either 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) or 1-palmitoyl-2-
oleoyl-glycero-3-phosphocholine (POPC) were combined with 0.1 mol% biotin-labeled 
phospholipid, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(biotinyl), in 
chloroform to form a 13.3 mM total lipid solution. All lipids were purchased from Avanti 
Polar Lipids, Inc. 4 µmol (300 µL) total lipid solution was placed in a 10 mL round 
bottom flask and heated to 50 ºC and dried using a rotatory evaporator (LabTech Srl) at 
60 rpm under vacuum for 5 minutes to form a thin lipid film. The film was then hydrated 
with 500 µL of 90 mM carboxyfluorescein (MilliporeSigma) in 1 M Tris buffer, pH 8, 
with 300 mM NaCl for 1 hour at 50 ºC with periodic gentle agitation. Hydrated lipids 
were then extruded through 100 nm, 1 µm, or 10 µm polycarbonate membrane 
(Whatman) 27 times using a manual extruder (Avanti Polar Lipids Inc.) at 50 ºC or room 
temperature for DPPC or POPC liposomes, respectively. Liposomes were separated from 
unencapsulated solution using a PD MiniTrap G-25 Sephadex column (GE Healthcare) 
using 300 mM NaCl in 1 M Tris buffer, pH 8, solution prior to use. Liposome size was 
characterized by dynamic light scattering using a Nanotrac Flex particle size analyzer 
(Microtrac). 
 
IRE treatment and dye release 
130 µL of prepared liposome solutions were placed in an electroporation cuvette (Fisher 
Scientific) with aluminum plate electrodes spaced 2 mm apart. The two electrodes were 
then connected to a BTX ECM 830 electrical pulse generator (Harvard Apparatus) in 
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order to induce a homogeneous electric field throughout the liposome solution. The 
electric field was determined by the dividing the applied voltage by the distance between 
electrodes. Liposomes were subjected to either 500, 1500, or 2000 V·cm-1, in 99 square 
pulses with 100 µs pulse duration at a frequency of 1 Hz. Release of encapsulated 
carboxyfluorescein following electroporation was determined from the fluorescence 
intensity of the solution. 100 µL of treated liposome solution was placed in a well of a 
black, round-bottom, 96-well plate and fluorescence intensity (490 nm/520 nm 
excitation/emission wavelengths) was quantified with a microplate reader (BioTek 
Instruments Inc.). For positive controls representing total release, liposomes were mixed 
in equal volume with 2% Triton X-100 (MilliporeSigma) to disrupt liposome assembly 
for complete release. Percent Release (%), was calculated using untreated negative 
controls and positive controls by the following formula: 
!"#$"%& !"#"$%" (%) =  !! − !−2∗!+ − !−×100 (4-1) 
where FS, F–, and F+, are the fluorescent intensities of treated sample, negative control, 
and positive control, respectively. 
 
4.3 Results and discussion 
4.3.1 Chemical modification of polymer scaffolds for protein conjugation  
Although similar microporous polymer scaffolds have previously been modified for 
controlled release of chemokines in vivo by incorporating chemokines in polymer 
microparticles through encapsulation or coating [42, 131], release rates depend on 
degradation of the polymer and are not inducible. As the goal of this work was to 
maximize the impact of adjuvant release by coupling it to the focal ablation, we sought to 
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incorporate the adjuvants in particles could release their cargo upon IRE. Fig. 4-1 
demonstrates the strategy for introducing drug-loaded particles onto the surface of 
polymer scaffolds. In the first step, the polymer surface will be modified with primary 
amines to facilitate attachment of streptavidin through 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC), a heterobifunctional 
crosslinker. Then, drug-loaded particles surface-labeled with biotin will be incubated 
with streptavidin-polymer scaffolds. This will result in particles being bound to polymer 
scaffolds due to the strong non-covalent binding between streptavidin and biotin [132].  
 
 
Figure 4-1. Schematic for attaching drug-loaded particles onto microporous polymer 
scaffolds. PCL scaffolds will be chemically modified with primary amines. EDC will be used to 
catalyze the covalent bond between the carboxyls on streptavidin and primary amines on 
modified PCL scaffolds. The strong streptavidin-biotin interaction will then facilitate binding of 
drug-loaded particles (green sphere) labeled with biotin (red square) to PCL scaffolds for 
inducible release. 
 
Heterobifunctional linkers have been used to conjugate proteins, such as brain-derived 
neutrophobic factor, to PCL scaffolds [133]. These heterobifunctional crosslinkers 
catalyze a covalent bond between two different functional groups that are naturally found 
in biological samples, such as primary amines, carboxylic acids, and sulfhydryl groups. 
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Commonly used heterobifunctional crosslinkers facilitate the conjugation between 
sulfhydryl-to-amine or carboxyl-to-sulfhydryl moieties to attach proteins to other target 
proteins or surfaces. Since the polymer backbone of PCL does not contain these active 
functional groups for the attachment of biological molecules [134], chemical 
modification of the polymer surface will be required prior to utilizing heterobifunctional 
linkers to attach streptavidin to the surface. Streptavidin is a protein that is composed of 
four identical polypeptide units that can each bind to one biotin molecule. The amino acid 
composition of this polypeptide lacks the cysteine required for conjugation involving 
sulfhydryl chemistry, but does contain 13 amino acids with carboxylic acid functional 
groups [135]. Thus, a widely used carboxyl-to-amine heterobifunctional linker, EDC, 
could be used to couple streptavidin to a surface containing primary amines to form 
stable amide bonds [136]. Introduction of amine groups to the surface of PCL scaffolds 
can be achieved through an aminolysis reaction. This reaction has been used in the textile 
industry to modify synthetic polyesters, such as poly(ethylene terephthalate), to improve 
properties such as wettability [137] and dyeability [138]. By utilizing small chain alkanes 
with multiple primary amine functional groups, such as ethylenediamine, aminolysis of 
biodegradable polyesters, such as PLG [134] and PCL [130], results in cleaved polymer 
chains with terminal primary amines (Fig. 4-2). 
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Figure 4-2. Aminolysis method to introduce primary amines to biodegradable polyesters. 
Ethylenediamine can be used to break the backbone of polyesters, such as PCL, to introduce 
primary amines, which may be utilized to attach proteins to polymer scaffolds. 
 
To optimize reaction conditions for introducing primary amines on the surface of PCL 
scaffolds, three different incubations with 0.05 M ethylenediamine were tested: 10 
minutes at room temperature, 24 hours at room temperature, and 24 hours at 37 ºC. To 
evaluate the yield of amines on the polymer surface following the reaction, the scaffolds 
were incubated with fluorescamine, which fluoresces upon reaction with a primary amine 
[139]. The fluorescence images of PCL scaffolds following aminolysis and fluorescamine 
labeling can be seen in Fig. 4-3A-D. PCL scaffolds treated without ethylenediamine (Fig. 
4-3A) served as a background control, and no noticeable difference in fluorescence 
intensity can be seen between controls and PCL scaffolds undergoing a 10-minute 
reaction time at room temperature (Fig. 4-3B). With longer reaction conditions, 24 hours, 
a noticeable increase in signal intensity is observed, with the greater intensity observed at 
elevated temperatures (Fig. 4-3D) in comparison to room temperature (Fig. 4-3C). These 
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observations were quantified by analyzing the fluorescence signal intensity from the 
images taken of each scaffold (Fig. 4-3E). Signal intensities were normalized to results 
from scaffold samples treated without ethylenediamine (Fig. 4-3A). Both 24-hour 
reaction conditions at room temperature and 37 ºC demonstrated significantly greater 
fluorescence signal intensity over background, with 24-hour reaction at 37 ºC yielding the 
greatest signal. This confirmation that primary amines can be incorporated onto the 
surface of PCL scaffolds indicates that streptavidin could be linked to these modified 
scaffolds using a carboxyl-to-amine heterobifunctional crosslinker, such as EDC, upon 
which drug-loaded particles with surface-labeled biotin could be conjugated to the PCL 
scaffolds through the strong molecular affinity between streptavidin and biotin. 
 
 
Figure 4-3. Evaluation of surface primary amines on PCL scaffolds through fluorescamine 
treatment. (A-D) Fluorescence imaging of microporous PCL scaffolds after no ethylenediamine 
(ED) reaction (A) or 0.05 M ethylenediamine in isopropyl alcohol at room temperature (RT) for 
10 minutes (B) or 24 hours (C), or at 37 ºC for 24 hours (D). All scaffolds were treated with 
fluorescamine to fluorescently label primary amines. Scale bar indicates 500 µm. (E) Average 
signal intensity taken from scaffold samples normalized to scaffolds treated without 
ethylenediamine. Intensity values were averaged over the three individual scaffold samples per 
reaction condition. Average intensity per scaffold was quantified from four separate images taken 
for each scaffold. (*) P < 0.001 compared to scaffolds treated without ethylenediamine. 
Normalized signal intensity data is mean ± SD, n = 3. 
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4.3.2 Drug-loadable carriers for IRE-inducible release 
Several forms of drug carriers have been formulated for inducible release. Local release 
of a payload for some systems can be triggered by small molecules. In one system, 
vascular endothelial growth factor (VEGF) was encapsulated in a polyacrylamide 
hydrogel, which contained non-covalent cross-links from a homodimeric binding protein, 
FK binding protein 12. Upon exposure to a competitive inhibitor, FK506, dissociation of 
the binding proteins expanded the hydrogel structure, causing release of encapsulated 
VEGF [140]. Another system encapsulated transgenic cell lines in a cellulose capsule. 
These transgenic cell lines were engineered to sense for a specific antibiotic, doxycycline 
or erythromycin, which would then induce expression of therapeutic proteins and the 
enzyme cellulase to break down the capsule, thereby releasing these therapeutics [141]. 
 
Inducible release caused by energy-based applications, such as heat and electroporation, 
has also been utilized. A common drug carrier for these applications is liposomes. 
Liposomes are self-assembled, spherical vesicles formed by a membrane bilayer 
commonly composed of phospholipids. Early uses of liposomes in the 1970s were for 
drug delivery, due to their ability to entrap both aqueous drugs in the interior and 
hydrophobic drugs within the lipid membrane [142]. Since then, the field of liposomes 
has progressed to clinical relevance with fifteen FDA-approved liposomal drug 
formulations for a wide variety of applications such as fungal infections, influenza, and 
even for treatment of metastatic breast and pancreatic cancer [143].  
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Release of encapsulated contents through heat from specific liposome formulations has 
also been extensively studied [144]. Above a critical temperature, the membrane of these 
thermo-sensitive liposomes becomes significantly more permeable, causing release of 
encapsulated drugs [128]. Thermo-sensitive liposomes loaded with chemotherapeutic 
drugs, such as doxorubicin, designed with a target release temperature above normal 
body temperature of 40-42 ºC, are being implemented in combination with focal 
hyperthermia. This combination therapy can increase the efficacy of treatment by 
destroying a larger portion of the tumor than focal hyperthermia alone by treating tumor 
cells at the periphery of thermal ablation through local release of chemotherapeutic drugs 
[145]. One such formulation, ThermoDox, is currently in phase III clinical trials for 
treatment of non-resectable liver cancer in combination with focal hyperthermia [146]. 
 
IRE can also trigger release from drug-loaded liposomes. In liposomes and cells, the lipid 
bilayer is electrically insulating, and high electric fields can cause membrane 
deformation, resulting in pores [71, 129, 147, 148]. These pores cause a significant 
increase in permeability, allowing encapsulated molecules to diffuse out. This 
phenomenon has been utilized in conjunction with IRE in vivo to treat human liver 
cancer, Hep3B, in mice. Intratumoral injection of liposomes loaded with the tumor 
suppressor NVP-BEZ235 [149] prior to IRE increased treatment volume and decreased 
cancer cell growth in comparison to IRE treatment alone [150]. Due to their applications 
as an effective drug carrier and their inducible release capability under IRE, liposomes 
will be investigated for inducible release with polymer scaffolds. 
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For attachment to scaffolds through streptavidin-biotin interaction, liposomal 
formulations containing biotin were prepared by a commonly used procedure [151-153]. 
A mixture of phospholipids with and without a biotin headgroup is dissolved in a polar 
organic solvent, such as chloroform, that reduces both hydrophobic and hydrophilic 
interactions (Fig. 4-4A). The chloroform is then evaporated off to produce a lipid thin 
film (Fig. 4-4B). Addition of an aqueous buffer causes the film to hydrate and swell and 
leads to the formation of liposomes with biotin incorporated in the membrane (Fig. 4-4C) 
[152, 154]. Extrusion through a nanoporous membrane is then applied to achieve a more 
uniform size distribution (Fig. 4-4D) [155]. 
 
 
Figure 4-4. Schematic of biotinylated liposome preparation. (A) Mixture of phospholipids 
with and without biotin in a polar organic solvent. (B) Production of lipid thin-film following 
evaporation of organic solvent. (C) Liposome formation from hydration of lipid films. (D) 
Extrusion of liposomes to control size distribution. 
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To quantify release following IRE treatment, an established release assay using 
carboxyfluorescein was implemented [127, 156-158]. Carboxyfluorescein is a fluorescent 
molecule that at high concentrations, ≥ 90 mM, becomes self-quenched, losing 97-98% 
fluorescence [156]. This self-quenching property can be used to quantify the amount of 
release from the liposomes, as the encapsulated carboxyfluorescein is at a sufficiently 
high concentration to become self-quenched, but the carboxyfluorescein released from 
liposomes following IRE treatment will become diluted in the surrounding medium, and 
fluorescence intensity can be correlated to the amount released. Two separate liposome 
characteristics, formulation and size, were investigated for their effect on release upon 
IRE. Two formulations were chosen such that the lipid bilayer would be in different 
phases at body temperature, a gel state and a liquid crystalline state. In the gel state, the 
phospholipid hydrocarbon chains are oriented in a straight fashion, perpendicular to the 
plane of the bilayer, resulting in a more dense and rigid membrane. Conversely in the 
liquid crystalline state, there is enhanced mobility of phospholipid hydrocarbons, causing 
more fluidity in the membrane [159]. The gel and liquid crystalline state occur below and 
above the phase transition temperature (TC), respectively [159, 160]. To evaluate each of 
these states, liposomes were prepared from either DPPC or POPC, which have a TC of 41 
ºC [161] and –2 ºC [162], respectively. Due to the stresses that electric fields cause on the 
lipid membrane, we hypothesized that lipid bilayers in the liquid crystalline state would 
be more prone to deformation, resulting in greater release.  
 
Size may also contribute to release, as theoretical models show that the voltage potential 
across a lipid bilayer of a liposome in an electric field is proportional to the diameter of 
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the liposome [163]. Thus, under a constant electric field the potential to introduce 
permanent pores into the lipid bilayer becomes diminished with decreasing liposome size. 
Liposomes of different sizes were prepared using polycarbonate membranes of 0.1, 1, or 
10 µm pore size during the extrusion process. Figure 4-5 shows the measured size 
distribution from DPPC and POPC liposomes using dynamic light scattering (DLS). 
POPC and DPPC liposomes prepared with 100 nm membranes resulted in a population of 
particles with a single peak and a mean size of 140 ± 40 nm and 130 ± 40 nm, 
respectively. Measurements following extrusion through 1 and 10 µm membranes 
demonstrated much broader distributions of liposome particles with multiple peaks 
present. For 1 µm samples, the mean size was 2.3 ± 1.3 µm for POPC liposomes and 1.8 
± 0.9 µm for DPPC liposomes, while 10 µm samples had a mean size of 2.8 ± 1.3 µm and 
3.0 ± 1.6 µm for POPC and DPPC liposomes, respectively. This broader distribution with 
larger membrane pore size has been observed in the literature [164], but could be 
improved by further refinement of the procedure or downstream fractionation with size 
exclusion chromatography. While there was a trend of increasing liposome size with 
increasing membrane pore size in Fig 4-5, the characterization of liposomes following 
extrusion through 10 µm membranes yielded particles much smaller than expected. Size 
distribution with DLS is determined by the fluctuations in scattered light intensity coming 
from the diffusion of particles in solution [165]. With larger particles, sedimentation due 
to gravity is more likely and can lead to inaccurate size characterization by DLS. 
Alternative strategies to measure liposome strategies that do not depend on diffusion, 
such as static light scattering and/or optical particle sizing will need to be explored. 
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Figure 4-5. Liposome size distribution. Signal intensity size distribution measured by DLS of 
POPC (top) and DPPC (bottom) liposomes. Liposomes were extruded through either a 100 nm 
(left), 1 µm (center), or 10 µm (right) polycarbonate filter. 
 
Release following electroporation from 90 mM carboxyfluorescein-loaded DPPC and 
POPC liposomes of various sizes was then evaluated in vitro. Liposome solutions were 
placed in an electrocuvette and connected to an electrical pulse generator to provide a 
homogeneous electric field throughout the solution during electroporation. Percent 
release following electroporation (Fig. 4-6) was quantified by the difference in release 
from untreated controls and liposome samples treated with detergent for complete 
carboxyfluorescein release through membrane disruption. DPPC liposomes showed a 
general trend of greater release with increases in electric field strength and membrane 
pore size, with the greatest percent release of 22 ± 6% achieved at 2000 V·cm-1 from 
DPPC liposomes prepared from membranes with a 10 µm pore size. These trends agree 
with theoretical predictions that the voltage potential across the membrane is directly 
proportionally with liposome size and applied electric field strength [163]. The increase 
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in transmembrane voltage potential can then result in membrane instability and pore 
formation, leading to carboxyfluorescein release. Due to the importance of liposome size, 
better characterization of the size distribution of DPPC liposomes following extrusion 
through 10 µm membranes could provide a better understanding of the size threshold 
needed for release. Purification of this population could lead to an increase in total 
release from IRE. 
 
 
Figure 4-6. Inducible release from liposomes following electroporation. (A-C) Percent release 
of carboxyfluorescein from POPC (blue) and DPPC (red) liposomes following electroporation 
with 99 pulses at 100 µm pulse duration at 1 Hz at either 500, 1500, or 2000 V·cm-1 on 100 nm 
(A), 1 µm (B), and 10 µm (C) liposome preparations. 100% total release was determined from 
detergent-mediated liposome disassembly and untreated samples were used as 0% release 
controls. Percent release is mean ± SD, n = 3. 
 
POPC liposomes, however, demonstrated less than 5% release, independent of applied 
condition or preparation. It was hypothesized that the POPC lipid bilayer would be more 
susceptible to pore formation due to the more fluid bilayer in comparison to the more 
rigid DPPC bilayer at room temperature. The difference in electrical properties, however, 
between the two transition states rather than the mechanical properties may have had the 
more important effect on carboxyfluorescein release. A study on DPPC lipid bilayers 
showed that the transmembrane voltage potential threshold for membrane instability 
increases by about 70% when the bilayer transitions from a gel state to a liquid crystalline 
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state [166]. This may be partly due to the observed increase in the membrane capacitance 
[166], which theoretical models predict that will decrease the voltage potential across the 
lipid bilayer [167]. Thus, the liquid crystalline state in membrane of POPC liposomes 
may have the reduced the transmembrane potential enough to reduce pore formation, 
even at elevated electric fields and liposome size.  
 
A study by Yi et al. investigated percent release of carboxyfluorescein from 200 nm 
liposomes in which the bilayer is in a liquid crystalline state at room temperature 
following electroporation [157]. They observed similar low amounts of release, ≤ 10%, 
with a weak dependence on electric field strength. Although better size characterization is 
needed to confirm that the POPC liposomes extruded from 10 µm membranes are larger 
than the samples prepared from 1 µm liposomes, the observed release of 
carboxyfluorescein from electroporation in this study may provide better insight into how 
size, electric field strength, and the thermodynamic state of the lipid bilayer affect total 
release. While many studies have shown that electroporation may be used to induce pores 
in liposomes for drug release, few have quantified the amount of content released, which 
may affect efficacy. 
 
4.4 Conclusions 
The purpose of this study was to evaluate systems for IRE-induced molecule release that 
can be coupled to polymer scaffolds. Due to the lack of functional chemical groups in 
PCL for conjugation of biomolecules, PCL scaffolds were modified through an 
aminolysis reaction to introduce primary amines to the surface. Through this change, 
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covalent linkage of streptavidin could be utilized in the future to couple biotin labeled 
drug carriers to the scaffold due to the strong affinity between streptavidin and biotin. 
Biotinylated liposomes were prepared as drug carriers due to their common use in drug 
delivery and potential for inducible release through electroporation. Liposomes 
comprised of either DPPC and POPC were prepared using membranes with varying pore 
size to achieve liposomes of different sizes as characterized by DLS. Percent release 
following electroporation at varying electric field strengths was quantified through a 
carboxyfluorescein release assay. Release from DPPC liposomes increased with liposome 
size and electric field strength while POPC liposomes showed minimal release 
independent of condition. The largest observed percent release of 22 ± 6% came from 
DPPC liposomes, which to our knowledge, is higher than what has been reported in the 
literature. Through this study, a greater understanding of how liposomal release through 
electroporation may be achieved by varying size, composition, and electric field strength 
as well as how these drug carriers may be integrated with polymer scaffolds capable of 
recruiting cancer cells was developed. 
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Chapter 5: Integration of tumor cell-capturing polymer scaffolds into mouse models 
of melanoma 
5.1 Introduction 
Recruitment of breast cancer cells to PCL scaffolds is mediated by the local metastatic 
immune environment [39]. Since the immune system plays a role in metastasis of many 
cancers, these scaffolds could potentially be used to recruit other types of tumor cells, 
such as melanoma cells. Similar to observations in breast cancer patients [168, 169], 
elevated levels of myeloid derived suppressor cells in the peripheral blood of melanoma 
patients are correlated with advanced disease [170, 171]. Interestingly, these myeloid 
derived suppressor cells also facilitate recruitment to both metastatic organs and polymer 
scaffolds in breast cancer [39]. The high cytotoxic T lymphocyte infiltration in the 
melanoma tumor microenvironment led to the discovery of tumor-specific cytotoxic T 
cells and their associated melanoma-specific antigens, such as MART-1 [172, 173], 
gp100 [174], and TRP-2 [118]. While these antigens are well-characterized, the vast 
majority of cancers lack well-defined tumor-antigens and often specific antigens vary 
from patient to patient [175]. As a consequence, melanoma is a prime model for 
monitoring an immune response [176] and can be used as a proof of principle model to 
evaluate optimal treatment conditions that lead to effective anti-tumor immunity, which 
may translate to cancers with undefined antigens. 
 
Recruitment of disseminated melanoma cells has previously been performed with other 
implantable devices [30, 38], and the recruitment of tumor cells has been shown to 
correlate with increased overall survival [38], which was also observed for studies using 
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PCL scaffolds to recruit disseminated breast cancer cells [41]. Thus, PCL scaffolds 
incorporated into mouse models of melanoma could be used as a platform to track 
immune response following focal ablation of disseminating tumor cells. Accordingly, 
Chapter 5 will investigate experimental and spontaneous metastasis, as described in 
Section 1.3, and direct seeding approaches to introduce melanoma cells to PCL scaffolds. 
 
5.2 Materials and methods 
Scaffold fabrication 
To fabricate polymer scaffolds, PCL and PLG microspheres were first prepared as 
previously described [39, 41]. Briefly, for PCL microspheres, a 6% (w/w) solution of 
PCL (DURECT; inherent viscosity = 0.65-0.85 dL·g-1) in dichloromethane was 
emulsified in a 10% (w/w) poly(vinyl alcohol) solution and homogenized at 10,000 rpm 
for 1 minute. For PLG microspheres, a 6% (w/w) solution of 75:25 PLG (DURECT; 
inherent viscosity = 0.55-0.75 dL·g-1) in dichloromethane was emulsified in a 1% (w/w) 
poly(vinyl alcohol) solution and homogenized at 7,000 rpm for 30 seconds. Microspheres 
were lyophilized for 48 hours and then mixed with sieved sodium chloride particles (250-
425 µm) in a 1:30 (w/w) ratio. Microsphere/sodium chloride mixtures were pressed to 
3,300 lbs. for 45 seconds in a 5 mm steel die (Specac). PCL pressed disks were heated at 
60 ºC for 5 minutes on each side and both types of polymer scaffolds were then foamed at 
800 psig for ~24 hours, after which the gas was released at 17.5 CFH. Salt particles were 
removed by immersing disks in water for 90 minutes on a rocking platform. Polymer 
scaffolds were sterilized by soaking in 70% ethanol, followed by rinsing with sterile 
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water and drying on a sterile gauze pad. Scaffolds were then stored at -80 ºC until further 
use. 
Scaffold implantation and tumor inoculation 
Animal studies were performed in accordance with institutional guidelines and protocols 
approved by the University of Minnesota Institutional Animal Care and Use Committee 
(IACUC). Female C57BL/6 mice were purchased from The Jackson Laboratory, and 
mice were 7-15 weeks of age at the time of surgery. Two scaffolds were implanted into 
the subcutaneous space of the upper dorsal region per mouse. For intraperitoneal 
injection of B16-F10-TFP cells, two days after scaffold implantation, 5E6 B16-F10-TFP 
cells in 200 µL of PBS were injected into the intraperitoneal cavity, and scaffolds were 
harvested at 2 and 42 days following inoculation. For intravenous injection of B16-TFP 
cells, three weeks after scaffold implantation, 5E5 B16-F10-TFP cells in 200 µL of PBS 
were injected through the tail vein, and scaffolds were harvested at 10, 14, and 20 days 
following inoculation. For the orthotopic spontaneous metastasis model, 4-6 weeks after 
scaffold implantation, 5E4 B16-BL6 cells were injected intradermally into either the right 
flank or the dorsal side of the left ear in 50 µL and 15 µL of PBS, respectively. Primary 
tumors were excised when they reached ~5 mm x ~5 mm size, which occurred after 11-
15 days for flank inoculation and 15-29 days for ear inoculation. Scaffolds were resected 
4-5 weeks post-tumor inoculation for both groups. For tumor-free controls, mice received 
inoculations of PBS without cancer cells. 
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Flow cytometry 
Mice were euthanized and scaffolds were retrieved, minced with microscissors in a 0.38 
mg·mL-1 solution of Liberase TL (Roche Applied Science) in Hank’s balanced salt 
solution (ThermoFisher Scientific) and placed at 37 °C for 20 min. Liberase was 
neutralized with 0.125 M EDTA (ThermoFisher Scientific), and cells were isolated by 
passing the digested tissue through a 70 mm filter (BD Biosciences) and rinsing with 
FACS buffer, PBS containing 0.5% bovine serum albumin (MilliporeSigma) and 2 mM 
EDTA. For analysis of TFP-positive B16-F10 tumor cells, samples were resuspended in 
FACS buffer and analyzed using an LSR II flow cytometer (Becton Dickinson 
Immunocytometry Systems). 
 
qRT-PCR analysis 
To evaluate the lower detection limit for TRP-2 in B16-F10 cells in vitro, B16-F10 
(ATCC CRL-6475) and 4T1 (ATCC CRL-2539) cells were mixed together at various 
ratios, while keeping the total cell population at one million cells. Cells were then placed 
in RLT buffer (Qiagen) with 1% β-mercaptoethanol (MilliporeSigma) and homogenized 
using QIAshredder columns (Qiagen), following the manufacturer’s instructions. 
Tumors, lungs, and scaffolds harvested for qRT-PCR analysis were immediately snap 
frozen in liquid nitrogen and stored at -80 ºC. For homogenization of tissues, samples 
were placed in RLT buffer with 1% β-mercaptoethanol and homogenized at 10,000 rpm 
for 20 seconds on ice. To minimize the risk of cross-contamination between samples, 
after homogenization of each sample, the homogenizer was washed with 3 rounds of 
Type 1 water, 2 rounds of 70% ethanol, and 2 rounds of 100% ethanol, followed by a 
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wash with ELIMINase (ThermoFisher Scientific) and then 4 rounds of Type 1 water 
washes before running the next sample. For all samples, total RNA extraction was then 
performed using the RNeasy Mini Kit (Qiagen) following the manufacturer’s 
instructions. cDNA synthesis was performed with 1 µg of total RNA for each sample 
using the Omniscript RT Kit (Qiagen). RT-PCR reactions were performed with 0.5 µL of 
cDNA, GoTaq Green Master Mix (Promega), and the gene-specific forward primer (250 
nM) and reverse primer (250 nM), and reactions were run for 30 cycles and separated 
using a 2% agarose gel at 100 V for 30 minutes. qRT-PCR reactions were performed with 
1 µL of cDNA, iTaq Universal SYBR Green Supermix (BioRad), and the gene-specific 
forward primer (250 nM) and reverse primer (250 nM). qRT-PCR analysis was 
performed using a CFX Connect Real-Time PCR Detection System (BioRad). Primers 
for GAPDH [90] and TRP-2 [97] were obtained from the literature and are summarized in 
Table 5-1. For each sample, relative expression of TRP-2 to reference gene GAPDH, 
CtTRP-2 – CtGAPDH, was obtained before fold change calculations were performed. 
 
Table 5-1. Primer sequences used for qRT-PCR analysis. 
Gene Forward (5’-3’) Reverse (5’-3’) 
GAPDH CAATGTGTCCGTCGTGGA GATGCCTGCTTCACCACC 
TRP-2 TTAGGTCCAGGACGCCCC CTGTGCCACGTGACAAAGGC 
 
Seeding scaffolds with melanoma cells 
For direct seeding of melanoma cells, luciferase-expressing B16-F10 cells (B16-F10-
Luc) melanoma cancer cells were suspended in 5 mg·mL-1 Matrigel (Corning) at 20E6 
cells per mL. To load cell solution within the hydrophobic pores of the polymer scaffolds, 
PCL scaffolds were submerged in 70% ethanol and then two rounds of culture media. 
 89 
Scaffolds were then partially dried on gauze pads for 5 minutes each side and 20 µL of 
B16-F10-Luc suspension in Matrigel was then loaded into each scaffold followed by a 5 
minute incubation at 37 ºC prior to subcutaneous implantation. 
Tissue sectioning and histological analysis 
For histological analysis, Matrigel only and B16-F10-Luc loaded scaffolds were removed 
whole from the subcutaneous space 11 days post-implantation. Tissues were fixed in 10% 
buffered formalin, embedded in paraffin, and sectioned at 4 µm using an HM 315 
microtome (Microm). Slides were stained with hematoxylin and eosin (H&E) for 
histological analysis. Slides were imaged using an EVOS FL Auto Microscope (Thermo 
Fisher Scientific). 
 
Bioluminescence imaging 
Ten minutes before imaging, mice were injected in the intraperitoneal cavity with 15 
mg·ml-1 of D-luciferin (Gold Biotechnology) in PBS at 75 mg·kg-1 body mass. For whole-
animal imaging, mice were anesthetized with inhaled isoflurane and in vivo luciferase 
expression was evaluated using the IVIS 100 Spectrum imaging system (Caliper Life 
Sciences). 
 
Statistical analysis 
Data are presented as the mean ± standard deviation (SD) or box and whisker plot when 
stated, and p-values were determined using an unpaired Student’s t-test. 
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5.3 Results and discussion 
5.3.1 Evaluation of PCL scaffolds in B16-F10 experimental metastasis model  
Recruitment of B16-F10 melanoma to engineered materials in experimental metastasis 
models has been previously demonstrated [30, 38]. In one study, B16-F10 cells were 
introduced into circulation through an intraperitoneal injection, which results in 
metastasis to the liver, kidney, peritoneum, and spleen [177]. A solution of polymer 
microparticles was injected into the dorsal subcutaneous space, and after 1 to 3 days, 
B16-F10 cells were injected into the intraperitoneal cavity of C57BL/6 mice [38]. 
Recruitment of melanoma cells to the polymer microparticles was observed one day after 
tumor cell injection, and recruitment was associated with the local acute inflammatory 
response present at the microparticle injection site one to three days following 
implantation. To evaluate if PCL scaffolds could recruit B16-F10 cells under similar 
conditions, PCL scaffolds were implanted in the dorsal, subcutaneous space of mice, and 
after two days, teal fluorescent protein (TFP)-expressing B16-F10 cells (B16-F10-TFP) 
were inoculated into the intraperitoneal cavity. B16-F10-TFP cells were utilized because 
recruitment could be quantified via flow cytometry (Fig. 5-1B) in comparison to 
unlabeled B16-F10 cells (Fig. 5-1A). As shown in Fig. 5-1B, a significant portion of the 
cells have lost expression of TFP during routing culture, indicating that analysis of the 
number of TFP-positive cells within the scaffolds will likely lead to an undercounting of 
the actual number of melanoma cells.  
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Figure 5-1. Fluorescence signature of TFP-labeled B16-F10 cells. (A, B) Representative flow 
cytometry data of cultured B16-F10 (A) and B16-F10-TFP (B) cells. Box indicates TFP-positive 
cells, with percentage of total cells that are TFP-positive indicated above the box. As the TFP-
labeled cells should not show fluorescence in the APC channel, APC expression is plotted against 
TFP expression to exclude false positives or auto-fluorescent cells. 
 
Scaffolds from mice that received only saline injections (Fig. 5-2B) were used as a 
baseline to compare to mice with B16-F10-TFP inoculations (Fig. 5-2A). Following a 
short (2 days) and long (42 days) melanoma exposure, scaffolds were harvested to 
evaluate recruitment of B16 cells (Fig. 5-2C). Aside from one outlier (Day 2), there was 
no evidence of recruitment of B16-F10-TFP cells to PCL scaffolds in this model. 
Although there was observable metastasis to the draining lymph node, no visible 
metastasis outside the peritoneum, such as the lung, was recorded (data not shown), as 
also seen by Fu et al. following IP inoculation of B16-F10 cells [177]. Given the lack of 
metastasis outside the peritoneal cavity and the inability to detect tumor cells in the 
scaffold, an alternative experimental metastasis model employing tail vein inoculation 
was evaluated for metastasis to PCL scaffolds, as this route of injection results in lung 
metastasis [177]. 
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Figure 5-2. Flow cytometry to quantify number of B16-F10-TFP cells recruited to 
implanted PCL scaffolds. (A, B) Flow cytometry analysis of cells isolated from PCL scaffold 
two days after intraperitoneal injection of saline (A) or B16-F10-TFP cells (B). Box indicates 
TFP-positive cells. (C) Number of TFP-positive cells from PCL scaffolds after 2 and 42 days post 
intraperitoneal injection of B16-F10-TFP cells. Each data point represents an individual scaffold. 
 
In order to study recruitment of cells to scaffold without confounding effects of the 
transient dynamics of the acute inflammatory response following implantation of the 
scaffold, we sought to perform the tail vein injection of tumor cells after the onset of the 
chronic inflammation stage within the scaffold. Previous work has shown that immune 
cell population within the scaffold stabilizes after ~30 days post-implantation [41]. Thus, 
B16-F10-TFP cells were injected intravenously through the tail vein four weeks after 
scaffold implantation to allow for both onset of the chronic immune microenvironment as 
well as sufficient vascularization. Scaffolds were harvested at 10, 14, and 20 days post-
inoculation, and the number of recruited B16-F10-TFP cells was evaluated with flow 
cytometry (Fig. 5-3). At Day 20, recruitment of B16-F10-TFP cells to PCL scaffolds was 
seen in multiple samples and visible macrometastases in the lung were observed (data not 
shown). Although the measured number of recruited cells is likely an underrepresentation 
because of TFP-negative cells present in B16-F10-TFP population, the number of cells 
recruited is likely too small for a robust immune response following focal therapy 
treatment. In addition, as this method is typically performed as a lung colonization assay, 
 93 
the majority of injected cells are localized to the lungs, complicating efforts to attract 
more circulating cells to the scaffold. Intravenous injection downstream of the lungs, 
such as through the left ventricle of the heart, could be implemented in the future to 
reduce lung colonization. Seib et al. utilized an intracardiac injection to demonstrate 
metastasis of B16-F10 cells to a bone-mimicking silk scaffold [30], which could be 
investigated with PCL scaffolds. 
 
 
Figure 5-3. Recruitment of B16-F10-TFP cells to PCL scaffolds following intravenous 
injection. Box and whisker plot of number of TFP-positive cells isolated from PCL scaffolds 10, 
14, and 20 days after intravenous injection of B16-F10-TFP cells. 
 
The use of flow cytometry, however, may be underrepresenting the number of recruited 
cells, independent of TFP expression heterogeneity. Extraction of single cells from 
scaffolds for flow cytometry involves many wash and rinse steps, leading to significant 
loss of material, which impacts the ability to quantify rare cells. Moreover, the loss of 
TFP protein expression in culture as observed in Fig. 5-1B could be compounded by 
additional signal loss in vivo [178], further diminishing the ability to obtain an accurate 
count of the number of tumor cells recruited to the scaffold. Lastly, the use of an 
experimental metastasis model may be limiting the recruitment of disseminated cancer 
cells to PCL scaffolds, as recruitment to these scaffolds has been associated with local 
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immune cell population changes caused by the primary tumor, and there is no primary 
tumor in experimental metastasis models. Thus, we explored spontaneous metastasis 
models of melanoma to assess recruitment of metastatic melanoma cells to the scaffold in 
mice that had primary tumors. 
 
5.3.2 Spontaneous metastasis model for recruitment of B16 cells to PCL scaffolds 
In order to evaluate the presence of unlabeled B16-F10 melanoma cells in PCL scaffolds, 
a qRT-PCR assay previously used to quantify metastasis of melanoma cells to the lung 
was utilized [97]. This assay quantifies metastasis by comparing the expression of 
melanoma-specific genes, such as TRP-2, in samples from mice with and without 
inoculation of melanoma cells. Due to the lower amount of tumor cells that might be 
present at the scaffold, as opposed to a solid tumor, the first step was to evaluate the 
lower detection limit for melanoma cells in a cell suspension using this assay. 
Accordingly, expression of TRP-2 in cell suspensions consisting of decreasing numbers 
of B16-F10 melanoma cells was analyzed using this qRT-PCR assay. To keep the total 
number of cells constant, 4T1 breast cancer cells were added to maintain the population 
number at 1 million cells. 4T1 cells were chosen because they are negative for TRP-2 
expression (Fig. 5-4A). The qRT-PCR data is plotted as fold change in TRP-2 expression 
normalized to samples containing only 4T1 cells, with glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) serving as a reference gene. The results show an increase in 
TRP-2 expression as the number of B16-F10 cells increases, and significant TRP-2 
expression compared to a population containing only 4T1 cells could be detected with as 
low as 10,000 B16-F10 cells, or 1% of total cell population (Fig. 5-4B). 
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Figure 5-4. qRT-PCR assay to identify the presence of B16-F10 cells. (A) RT-PCR of B16-
F10 melanoma and 4T1 breast cancer cells for melanoma-specific antigen TRP-2. GAPDH was 
used a housekeeping gene. (B) Fold change in TRP-2 expression in samples of 1E6 total cells 
containing various ratios of B16-F10 and 4T1 cells. Fold change is normalized to 4T1 controls 
(zero B16-F10 cells). (*) P < 0.05 compared to 4T1 control samples. qRT-PCR data is mean ± 
SD, n = 4. 
 
To validate that the qRT-PCR assay could detect unlabeled melanoma cells that have 
metastasized from the primary tumor in vivo, the B16-BL6 cell line was used, as it is a 
more metastatic variant derived from the B16-F10 cell line, and B16-F10 cells do not 
metastasize effectively in spontaneous tumor models [27]. B16-BL6 cells were 
inoculated through an intradermal injection on the right flank of C57BL/6 mice To 
prolong exposure to metastasizing tumor cells, the primary tumors were resected 11-15 
days later, leaving behind only disseminated melanoma cells in the mouse, as if the 
primary tumor is not resected the study must be terminated much sooner due to the size 
of the tumor. After at least four weeks following tumor resection, lungs were harvested 
and inspected for any visible melanoma nodules originating from the primary tumor. 
Lungs with and without visible macrometastasis (VM+ and VM– lungs, respectively) 
were analyzed for TRP-2 expression using the qRT-PCR assay (Fig. 5-5B). An example 
of a VM+ lung is shown in Fig. 5-5A). As expected, VM+ lungs had significantly greater 
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TRP-2 expression in comparison to naive lungs, but more importantly, Fig. 5-5 shows 
that the same is true for VM– lungs. These results demonstrate the capability of this qRT-
PCR assay to detect disseminated melanoma cells regardless of whether metastases are 
visually evident. The qRT-PCR assay has only been previously applied to detect 
metastasis from a tail vein injection model [97], in which the number of circulating tumor 
cells would be much higher than that of a more physiologically relevant orthotopic 
spontaneous cancer model. This analysis highlights the use of qRT-PCR as an effective 
assay for sensitive detection of disseminated cells from an orthotopic primary tumor. 
 
 
Figure 5-5. Detection of melanoma-specific gene expression in lungs from spontaneous 
metastasis model using qRT-PCR. (A) Picture of mouse lung with a visible macrometastasis 
nodule indicated by white arrow. (B) Fold change in TRP-2 expression in lungs with, VM+, or 
without, VM–, visible macrometastases following intradermal inoculation of B16-BL6 cells in 
right flank. Fold change is normalized to naive lung controls (*) P < 0.05 compared to naive 
lungs. qRT-PCR data is mean ± SD, n = 2 for naive lung and n =4 for VM– and VM+ lungs. 
 
The qRT-PCR assay was then applied for detection of melanoma cells that may have 
metastasized to PCL scaffolds. PCL scaffolds were implanted into the dorsal, 
subcutaneous space, and after at least four weeks, B16-BL6 cells were inoculated through 
an intradermal injection. Two independent injection sites, the flank and ear, were used 
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since the site of injection could impact routes of metastasis. Equal numbers of B16-BL6 
cells were inoculated at each location, and primary tumors were resected once they 
reached ~5 mm by ~5 mm in size, which occurred at 11-15 and 15-29 days post-
inoculation in the flank and ear, respectively. Apart from the differences in tumor growth, 
there was also variation in visible metastasis to the lungs and draining lymph nodes 
between the two orthotopic sites (Fig. 5-6A). Greater frequency of lung metastasis was 
seen in the flank model (32%) over the ear model (23%), but interestingly 31% of mice 
exhibited draining lymph node metastasis in the ear model, which was not observed in 
the flank model. PCL scaffolds were then harvested and analyzed for metastasis using the 
qRT-PCR assay (Fig. 5-6B). Fig. 5-6B shows that there is significantly greater TRP-2 
expression in PCL scaffolds from flank B16-BL6 orthotopic inoculations relative to PCL 
scaffolds harvested from tumor-free mice, providing evidence that melanoma cancer cells 
metastasized to the scaffold. Alternative assays, such as histological analysis, would be 
needed to confirm these findings, but these results would be the first to demonstrate 
recruitment of melanoma cells to an engineered site from an orthotopic primary tumor. 
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Figure 5-6. Evaluation of melanoma cell recruitment in a spontaneous orthotopic metastasis 
models. (A) Frequency of visible metastasis in the lungs and draining lymph nodes in mice 
following intradermal inoculation of B16-BL6 cells in right flank (blue) or left ear (red). (B) Fold 
change in TRP-2 expression in scaffolds from mice following intradermal inoculation of B16-
BL6 cells in right flank (blue) or left ear (red). Fold change is normalized to scaffolds from mice 
receiving saline inoculations as controls. (*) P < 0.05 compared to saline inoculation controls. 
qRT-PCR data is mean ± SD, n = 5 for naive scaffolds, n =13 for flank inoculations, and n = 14 
for ear inoculations. 
 
The differences in metastatic profile and recruitment of melanoma cells to the scaffold 
from flank and ear inoculations may provide insight into whether blood vessels or 
lymphatics are the primary route of metastasis to the scaffold, which remains unknown 
even in the context of breast cancer. The correlation between recruitment to the scaffold 
and increased visible lung metastasis from flank inoculations may imply that melanoma 
cells metastasize to the scaffold primarily through blood vessels. This is in agreement 
with the absence of melanoma recruitment to the scaffold from ear inoculations that 
resulted in draining lymph node metastasis, suggesting that lymphatics may not be the 
primary route of metastasis to the scaffold. Additionally, recruitment of melanoma cells 
to PCL scaffolds (Fig. 5-3) alongside lung metastasis was observed under tail vein 
injections. Furthermore, no visible lung metastasis and poor metastasis to PCL scaffold 
(Fig. 5-2C) was seen under intraperitoneal injections, but draining lymph node metastasis 
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was visibly detected. Altogether, studies that resulted in greater visible lung metastasis 
over draining lymph node metastasis also led to an increased frequency in recruitment of 
melanoma cells to PCL scaffolds. This may indicate that blood vessels are the primary 
route of metastasis to PCL scaffolds, but further studies will be needed to confirm these 
findings.  
 
5.3.3 Direct seeding of B16-F10 cells in polymer scaffolds prior to implantation 
Given the challenges in recruiting large numbers of melanoma cells to the scaffold, direct 
seeding of B16-F10 tumor cells in the scaffolds was explored as an alternative to enable 
proof-of-principle studies of combined focal ablation and immunomodulation of the 
scaffold site. PCL scaffolds were utilized for the studies described thus far due to their 
slower degradation rates in the body [179], which renders them appropriate for use in 
long-term studies. For shorter-term direct seeding studies, PLG scaffolds were also 
evaluated to determine which type of polymeric scaffold was more conducive to 
supporting tumor cell survival and growth. 4E5 luciferase-expressing B16-F10 melanoma 
cells (B16-F10-Luc) were suspended in Matrigel and loaded into either PCL or PLG 
scaffolds and implanted into the dorsal subcutaneous space in immunocompetent 
C57BL/6 mice. B16-F10-Luc cells were used for this study to enable whole-animal 
bioluminescence imaging to track tumor cell growth in the scaffold site throughout the 
study. After 11 days, scaffolds were harvested and analyzed by histology for the presence 
of B16-F10-Luc melanoma cells within the polymer scaffolds. H&E-stained sections of a 
primary tumor generated following an intradermal injection of B16-F10-Luc cells in the 
right flank shows the cellular morphology and staining profile of B16-F10-Luc cells in 
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vivo (Fig. 5-7), which exhibit typical malignant features, such as variability in size and 
shape of cytoplasm and nucleus, increased ratio of nucleus to cytoplasm, and prominent 
nucleoli [180]. After 11 days, Matrigel-loaded PCL scaffolds (Fig. 5-8A) show enhanced 
host cell infiltration in comparison to Matrigel-loaded PLG scaffolds (Fig 5-8B), which is 
consistent with previous observations [41]. However, when B16-F10-Luc cells are loaded 
into the scaffolds along with the Matrigel, the PLG scaffolds (Fig. 5-8D) demonstrate a 
greater presence of B16-F10-Luc cells than the PCL scaffolds (Fig. 5-8C) after 11 days.  
 
 
Figure 5-7. H&E staining of B16-F10-Luc primary tumor. Histological section of a B16-
F10-Luc primary tumor stained with H&E to demonstrate typical tumor cell morphology and 
staining profile. Light pink areas denote areas of tumor necrosis, characteristic of growing 
tumors. Scale bar indicates 100 µm. 
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Figure 5-8. Matrigel-only and B16-F10-Luc melanoma cell loaded polymer scaffolds post 
implantation in vivo. (A-D) H&E stained sections of (A, B) Matrigel-only loaded PCL (A) and 
PLG (B) scaffolds and (C, D) B16-LUC loaded PCL (C) and PLG (D) scaffolds harvested after 
11 days post-implantation in the dorsal, subcutaneous space in C57BL/6 mice. Scale bar indicates 
50 µm. 
 
Bioluminescence imaging was also used to track growth of B16-F10-Luc cells in real 
time. This imaging technique works by sensitive detection of light emitted by luciferase-
mediated oxidation of luciferin, a molecular substrate [181]. The detection level for 
imaging can be as deep as several centimeters, so growth of luciferase expressing B16-
F10-Luc cells within the scaffold can be measured in vivo. Greater signal intensity from 
implanted PCL (Fig. 5-9A) and PLG scaffolds (Fig. 5-9B) loaded with B16-F10-Luc 
cells is evident after seven days post-implantation in comparison to Matrigel-only 
controls. Images show that the B16-F10-Luc growth is localized within the scaffold 
region for both PCL and PLG scaffolds. Signal intensity was tracked over time (Fig. 5-
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9C) and as reflected by the histological results, more growth of B16-F10-Luc cells was 
observed in PLG scaffolds compared to PCL scaffolds. 
 
The contrast in cell infiltration and B16-F10-Luc presence might be explained by the 
differences in chemical composition of the two scaffolds. PCL and PLG are polyesters 
that degrade by hydrolysis, and differences in their degradation rate are dependent on 
their hydrophilicity. PCL is more hydrophobic than PLG, resulting in PLG degrading 
about 4-6x faster than PCL [179]. The byproducts of degradation are acidic molecules 
that can lower the pH of the local microenvironment, with the degradation products of 
PLG, lactic acid (pKa 3.08) and glycolic acid (pKa 3.83), being stronger acids than that 
of PCL, caproic acid (pKa 4.84) [182]. The combination of faster degradation and 
stronger acidic byproducts in PLG over PCL may have lead to toxic conditions for 
healthy cell infiltration in PLG scaffolds as seen in Fig. 5-8A-B. These results correlate 
with previous studies [41] and also by Sung et al. following subcutaneous implantation of 
PCL or PLG scaffolds [183]. An acidic microenvironment, however, may not necessarily 
be an inhibitor for B16-F10-Luc growth, as tumor microenvironments are commonly 
acidic [184]. Greater growth of B16-F10-Luc cells in PLG scaffolds may also be 
attributed to the more hydrophilic surfaces, which is favorable for cellular adhesion 
[185]. Hydrophilicity may affect cellular attachment by affecting how extracellular 
matrix proteins, such as fibronectin, adsorb to the polymer surface, which plays an 
important role in cellular attachment to solid substrates [186]. 
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Figure 5-9. Tracking growth of B16-F10-Luc cells in polymer scaffolds in vivo. (A, B) 
Bioluminescence imaging of mice at day 7 post subcutaneous implantation of PCL (A) and PLG 
(B) scaffolds loaded with either Matrigel-only control (left) or luciferase-expressing B16-F10 
cells (right). (C) Radiance intensity from B16-F10-Luc loaded scaffolds over time. Radiance data 
is mean ± SD, n ≥ 6. 
 
These results show that both PLG and PCL scaffolds could be used to locally maintain 
B16-F10-Luc melanoma cells in vivo following direct seeding, with PLG scaffold 
promoting better growth than PCL scaffolds. Previous reports have shown that other 
cancer cell recruiting scaffolds have been used to support cancer cells upon direct seeding 
in vivo, such as PC-3 prostate cancer cells in bone-mimicking, silk scaffolds [30]. This 
method of direct seeding of melanoma cells, however, does not reflect any stages in the 
metastatic process, and a spontaneous metastasis model would better represent metastasis 
of melanoma cells to the polymer scaffold. Nevertheless, directly seeding scaffolds with 
B16-F10 melanoma cells could be useful as a proof of principle to release tumor antigens 
from the scaffold following focal therapy and track the resulting immune response. 
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5.4 Conclusions 
Melanoma’s well-characterized antigens, such as TRP-2, make this cancer an ideal model 
to understand how anti-tumor immunity could be achieved following focal ablation of 
disseminating cells. In this chapter, microporous polymer scaffolds previously shown to 
recruit metastatic breast cancer cells [39] were evaluated for the ability to recruit 
melanoma cells, ultimately to track an immune response following focal therapy in future 
studies. Flow cytometric analysis of cells isolated from polymer scaffolds showed 
recruitment of fluorescently labeled B16-F10-TFP cells after 20 days following 
intravenous inoculation. Additionally, the recruitment of metastatic cells in a more 
clinically relevant orthotopic spontaneous metastasis model was evaluated using 
unlabeled B16-BL6 cells, a more metastatic variant of the B16-F10 line. A qRT-PCR 
assay previously used to quantify metastasis to the lung [97] was applied to polymer 
scaffolds to detect unlabeled melanoma cells both in vitro and from ex vivo samples. 
Analyzing relative gene expression of melanoma-specific TRP-2 through qRT-PCR 
provided evidence of recruitment to PCL scaffolds following intradermal inoculation in 
the flank. Aside from using metastatic models to isolate melanoma cells in vivo, PLG 
scaffolds supported growth of melanoma cells in vivo after being loaded directly into the 
scaffolds prior to subcutaneous implantation. This study demonstrates the ability of 
polymer scaffolds to be used as a system to recruit or support growth of metastatic 
melanoma cells, which in the future may be used to track an immune response following 
focal therapy. 
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Chapter 6: Conclusions and future directions 
6.1 General conclusions 
The aim of this project was to improve the therapeutic potential of microporous polymer 
scaffolds capable of recruiting metastatic breast cancer cells in vivo. Initial work focused 
on introducing focal therapy ablation, such as focal hyperthermia, to target metastatic 
cells that may be recruited to the polymer scaffold. This was first accomplished by 
modifying PCL scaffold to include an aluminum disk in the center for non-invasive 
induction heating through an alternating magnetic field. Heat generation could be 
controlled by the size of the disk, magnetic field strength, and type of metal. After 
subcutaneous implantation, these PCL-Al composite scaffolds were biocompatible and 
integrated properly with the host tissue, while maintaining the capacity to recruit murine 
breast cancer cells. In vivo induction heating of implanted PCL-Al scaffolds resulted in 
effective killing of host cells within the scaffold. 
 
The release of tumor specific antigens from the scaffold due to the ablation of tumor cells 
could potentially be utilized to induce an immune response to kill remaining cancer cells 
systemically. Thus, the combination of immunotherapy following focal ablation of 
disseminated cancers could further improve the beneficial effects of the polymer scaffold. 
Using well-characterized melanoma-specific antigens of the B16 cancer model to track in 
vitro T cell activation, collaborative work with the Shimizu and Bischof groups 
demonstrated that tumor lysates generated from IRE generated the greatest T cell 
activation compared to heat and cryogenic ablation. As a consequence, application of IRE 
within polymer scaffolds was studied. PCL scaffolds were modified to include metal 
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mesh electrodes (termed PCL-IRE scaffolds) to provide a more uniform electric field 
distribution than traditional two-probe geometry. B16 cells loaded into these PCL-IRE 
scaffolds were killed upon in vitro IRE treatment, demonstrating their efficacy for 
facilitating IRE application against melanoma cells. Composite PCL-IRE scaffolds 
integrated properly with tissue post-implantation and were capable of complete ablation 
of infiltrating cells within the scaffold in vivo. 
 
Electroporation of the scaffold could in theory also be utilized to induce release of 
immunoadjuvants from drug-loaded carriers attached to the scaffold in order to enhance 
the local immune response to the tumor antigens released upon ablation. To this end, PCL 
scaffolds were chemically modified with primary amines to facilitate streptavidin 
conjugation, enabling binding of biotin-labeled liposomes to the scaffold. In vitro release 
studies of liposomes in suspension following IRE treatment demonstrated that release 
could be tuned by electric field strength and liposome formulation and size. 
 
Finally, polymer scaffolds were evaluated for recruitment of melanoma cells in vivo, 
using both experimental and spontaneous metastasis models. In experimental metastasis 
models using the B16-F10 cell line, recruitment of tumor cells to the scaffold was seen 
upon tail vein injection of tumor cells but not intraperitoneal injection. A more metastatic 
variant, B16-BL6, was used to study metastasis from an orthotopic injection at either the 
lower flank or the ear. Using a qRT-PCR assay to quantify metastasis to implanted 
scaffolds, recruitment of melanoma cells was observed under flank inoculations. An 
increased presence of draining lymph node metastasis in intraperitoneal injections and ear 
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inoculations in contrast to more observable metastasis to the lungs from tail vein 
injections and flank inoculations may indicate that route of metastasis to the scaffold is 
predominantly through blood vessels as opposed to lymphatics. While the scaffolds are 
capable of recruiting metastasizing melanoma cells, should proof-of-principle studies of 
combined focal ablation and local immunomodulation of the scaffold site require larger 
numbers of tumor cells present at the site, B16 cells may be directly seeded into polymer 
scaffolds and maintain viability after 10 days post subcutaneous implantation. This 
project has shown that polymer scaffolds may be modified for focal therapy applications 
and are capable of recruiting metastatic melanoma cells, while providing many 
opportunities for further investigation. 
 
6.2 Future directions 
6.2.1 Sublethal hyperthermia for inducible release within PCL-IRE scaffolds 
In Chapter 4, IRE inducible release from polymer scaffolds using liposomes was 
explored. Although some release was observed from liposomes under IRE, the 
effectiveness may be a limited by diminishing effects of electroporation on vesicles of 
smaller size [163]. However, the use of heat has been successfully utilized to induce 
release within certain liposomal formulations [128]. These thermosensitive liposomes 
could be designed to release their cargo in the range of 40-42 ºC, which above body 
temperature but below a therapeutic threshold to kill cells [128]. As described in Chapter 
3, in vitro T cell activation studies have shown that melanoma cell lysates produced by 
IRE caused the greatest T cell activation in comparison to heat and cryogenic ablation. 
While heat may not be the optimal method for cell lysis to release tumor antigen, the 
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application of lower levels of heating to release immune adjuvants from thermosensitive 
liposomes prior to or after IRE treatment could enhance downstream immune activation. 
Immune adjuvants such as anti-CD40 antibody [187], unmethylated CpG 
oligodeoxynucleotides [188], and OK-432 [189] could be investigated as they have all 
been previously used in conjunction with focal therapy to improve outcomes in vivo. 
 
As shown in Chapter 2, a conducting material, such as an aluminum disk, could be used a 
heat source under an alternating magnetic field. The stainless steel metal mesh electrodes 
incorporated into PCL-IRE scaffolds for generation of a semi-uniform electric field in 
Chapter 3 could also serve a source of heat under electromagnetic induction. Although 
the temperature rise can be controlled by the applied magnetic field strength and 
frequency for a fixed electrode geometry and size, the difficulty in monitoring 
temperature levels to be sufficient for liposome release but below the threshold for cell 
damage may be impractical. Alternatively, the use of magnetic metals with a Curie 
temperature at 42 ºC could self-regulate heating rate without temperature monitoring 
[190]. While non-magnetic metals, such as aluminum, generate heat through eddy 
currents under electromagnetic induction, magnetic metals generate additional heat from 
the internal friction between magnetic domains during the rapid reversals in 
magnetization [191]. Above the Curie temperature, magnetic materials become 
nonmagnetic causing heat generation to drop significantly [190]. Magnetic metals such as 
manganese arsenide, MnAs, have a desired Curie temperature of 42 ºC [192], which 
could serve to provide heating to temperatures appropriate for liposome release but 
insufficient for cellular damage. 
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The use of a non-uniformly distributed heat source, however, results in temperature 
gradients throughout the scaffold. These temperature gradients may cause regions of low 
temperatures insufficient for liposome release. The use of a more dispersed heat source 
could also be explored to generate a more homogeneous temperature distribution, 
ensuring liposome release throughout the entire scaffold. This could be accomplished by 
encapsulating magnetic nanoparticles into PCL microparticles prior to fabricating 
scaffold by using a double emulsion technique previously used to encapsulate 
macromolecules such as DNA [193], proteins [194], and viruses [195]. Under an 
alternating magnetic field, magnetic nanoparticles generate heat by the dynamically 
changing internal magnetic moments and by the particle oscillations in the suspended 
medium [196]. Most common forms of magnetic nanoparticles for induced heating are 
composed of iron oxides magnetite, Fe3O4, and maghemite, γ-Fe2O3, which have been 
applied in the clinic to treat glioblastoma multiforme through an intratumoral injection 
[197]. These iron oxide nanoparticles have also been embedded in PCL scaffolds for 
homogeneous heat generation [85, 86]. Although these iron oxide nanoparticles were 
useful for focal hyperthermia, the Curie temperature of magnetite, 580 ºC [198], and 
maghemite, 600 ºC [199], would not allow for a controlled temperature rate below 
therapeutic temperatures. Alternative materials, such as Ba2FeReO6 [200] and Me1-
xZnxFe2O4 (x= 0.4-0.5; Me = Ni, Cu, Co, Mn) [201] nanoparticles, have been discovered 
with a Curie temperature of 42 ºC and could be used as self-regulating magnetic 
nanoparticles for homogeneous liposome release within the scaffold. The use of sublethal 
hyperthermia for inducible release of immune adjuvants from thermosensitive liposomes, 
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in combination with IRE therapy, may improve downstream immune action following 
treatment of disseminated cancer cells. 
 
6.2.2 Investigating primary route of metastasis to PCL scaffolds 
PCL scaffolds capable of recruiting 4T1 breast cancer cells [41] were investigated in 
Chapter 5 for capture of B16-BL6 melanoma cells. In the B16-BL6 model, differences in 
metastatic profile were observed depending on the orthotopic inoculation site of either the 
flank or ear. Flank inoculations led to observations of visible lung metastasis with no 
visible draining lymph node metastasis, while draining lymph node metastasis was more 
prevalent than lung metastasis under ear inoculations. Recruitment of B16-BL6 cells to 
the scaffold was observed from the flank inoculations and not the ear, suggesting that 
recruitment of B16 metastatic cells to the scaffold may be primarily through blood 
vessels and not through the lymphatics. As the route of metastasis of PCL scaffolds 
remains an unanswered question, even in the context of breast cancer, these observations 
in the melanoma model enable further investigations to provide deeper insight into 
whether the blood or lymph vessels are the primary route of metastasis to PCL scaffolds. 
 
To accomplish this, PCL scaffolds loaded with either angiogenic factors, such as FGF or 
VEGF-A, or lymphangiogenic factors, such as VEGF-C or VEGF-D, [202] could be used 
to compare recruitment to regular PCL scaffolds. The local release of these factors could 
increase the local density of either blood or lymph vessels within the scaffold. Increases 
in blood [203] and lymph [204] vessel density have been correlated with greater 
metastasis in human patients. Validation of local increase in blood or lymph vessel 
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density can be quantified with immunological staining of PAL-E or LYVE-1, 
respectively [205], in loaded PCL scaffolds post-implantation. Next, 4T1 breast and B16-
BL6 melanoma orthotopic tumor models could be utilized to determine differences in 
recruitment between angiogenic, lymphangiogenic, and regular scaffolds and to see 
whether the findings are specific to a each type of cancer. This study may provide a 
greater understanding of the primary route of metastasis to PCL scaffolds and thus may 
predict how best to utilize the scaffolds clinically. 
 
6.2.3 Downstream immune response following IRE of B16 cells in PLG scaffolds 
In Chapter 5, B16-F10 cells were directly seeded onto PLG scaffolds and implanted 
subcutaneously, as a proof-of-concept of presenting B16-F10 cells in the scaffolds for 
focal therapy. To study potential downstream immune activation from targeting 
disseminated cells, changes in endogenous levels and activation of TRP-2 specific T cells 
before and after IRE could be analyzed by flow cytometry. An increase in TRP-2 specific 
T cell levels may not be sufficient for anti-melanoma immunity [206]; thus, a secondary 
challenge of B16-F10 cells will be given to observe differences in tumor growth 
following the focal therapy. As it is likely that smaller numbers of tumor cells will be 
present in the scaffold as a result of metastasis, a titration of seeded B16-F10 cells could 
be utilized to determine how the quantity of tumor cells may affect immune response and 
to identify conditions that can produce the most robust response at low tumor cell 
numbers. The use of immune checkpoint blockade inhibitors, such as anti-PD-1 
monoclonal antibody, could be implemented to improve intended outcomes. 
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